aldosterone has been researched along with Fibrosis in 280 studies
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Angiotensin II and aldosterone often collaborate in pathological situations to induce hypertrophy of cardiomyocytes, vascular inflammation, perivascular and interstitial fibrosis, and microvascular rarefaction." | 8.89 | Aldosterone mediates cardiac fibrosis in the setting of hypertension. ( Azibani, F; Chatziantoniou, C; Delcayre, C; Fazal, L; Samuel, JL, 2013) |
| "Both aldosterone and arginine vasopressin (AVP) are produced in the heart and may participate in cardiac fibrosis." | 8.12 | Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction. ( Gao, X; Li, J; Lu, G; Peng, L; Zhai, YS, 2022) |
| "Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis." | 7.85 | Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017) |
| " This study suggests that telmisartan (TEL) can inhibit myocardial fibrosis of hypertensive left ventricular hypertrophy (LVH) through the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway." | 7.80 | Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway. ( Guan, G; Ma, A; Shao, L; Tian, G; Wang, J; Wang, Y; Zhang, Y, 2014) |
| "The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood." | 7.80 | Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014) |
| " The authors hypothesized that reduction in aldosterone production in diabetes by amlodipine or aliskiren improves diabetic kidney disease by attenuating renal oxidative stress and fibrosis." | 7.79 | Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. ( Matavelli, LC; Siragy, HM, 2013) |
| "To investigate the in vivo and in vitro protective effects of pentamethylquercetin (PMQ), a member of polymethoxy flavonoids (PMFs), on cardiac hypertrophy." | 7.78 | In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. ( Chen, L; Chen, Y; Han, Y; He, T; Jin, MW; Yang, WQ, 2012) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 7.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 7.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR." | 7.74 | [Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008) |
| " To elucidate its significance for myocardial fibrosis in the hypertensive heart, we used a mouse model with infusion of angiotensin II and examined results by histology, immunohistochemistry, in situ hybridization, and quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)." | 7.74 | Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. ( Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T, 2007) |
| "We recently demonstrated that both lisinopril and candesartan, an angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker, respectively, attenuate pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori (WBN/Kob) rats." | 7.73 | Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. ( Ando, T; Itoh, M; Joh, T; Kuno, A; Masuda, K; Nakamura, S; Nomura, T; Ogawa, K; Ohara, H; Okamoto, T; Shirai, T; Tang, M; Yamada, T, 2005) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 7.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| " Since chronic inhibition of nitric oxide (NO) synthase with N(omega)-nitro-L-arginine methyl ester (L-NAME) induces systemic hypertension associated with cardiovascular inflammation and remodeling, we examined the potential role of aldosterone in this process using eplerenone, a selective aldosterone receptor antagonist." | 7.73 | The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. ( Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L, 2006) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 7.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| "We evaluated the role of aldosterone as a mediator of renal inflammation and fibrosis in a rat model of aldosterone/salt hypertension using the selective aldosterone blocker, eplerenone." | 7.72 | Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. ( Blasi, ER; Blomme, EA; McMahon, EG; Polly, ML; Rocha, R; Rudolph, AE, 2003) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 7.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "In congestive heart failure, angiotensin-converting enzyme inhibitors (ACEIs) may prevent cardiac fibrosis via interaction with both angiotensin II and endothelin-1, which enhance myocardial collagen synthesis." | 7.72 | Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. ( Dohke, T; Eguchi, Y; Fujii, M; Horie, M; Isono, T; Matsumoto, T; Ohnishi, M; Takayama, T; Tsutamoto, T; Wada, A; Yamamoto, T, 2004) |
| "These results show that in old normotensive rats, spironolactone can markedly prevent cardiac and, to a lesser extent, arterial fibrosis and improve arterial stiffness, despite a lack of hypotensive effect." | 7.71 | Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. ( Benetos, A; Labat, C; Lacolley, P; Ledudal, K; Lucet, B; Safar, ME, 2001) |
| "Increased endothelin-1 (ET-1) or aldosterone may be associated with promotion of cardiovascular hypertrophy and fibrosis." | 7.71 | Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. ( Park, JB; Schiffrin, EL, 2002) |
| "Chronic administration of either angiotensin II (Ang II) or aldosterone (ALDO) leads to myocardial fibrosis." | 7.70 | Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. ( Ramires, FJ; Sun, Y; Weber, KT, 1998) |
| " This increase is mediated primarily by cardiac angiotensin II via AT1-subtype receptor and may be involved in post-MI ventricular fibrosis and in control of tissue norepinephrine concentration." | 7.70 | Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. ( Aupetit-Faisant, B; Carayon, A; Delcayre, C; Heymes, C; Oubénaïssa, A; Robert, V; Silvestre, JS; Swynghedauw, B, 1999) |
| "Myocardial fibrosis, associated with increased expression of angiotensin converting enzyme (ACE) and bradykinin (BK) receptor binding at sites of tissue repair, accompanies chronic elevations in circulating angiotensin II (AngII) and/or aldosterone (ALDO) that simulate chronic cardiac failure." | 7.69 | Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. ( Ramires, FJ; Sun, Y; Weber, KT, 1997) |
| "In order to determine the relation between myocardial fibrosis and (1) angiotensin converting enzyme (ACE) binding density, (2) receptor binding of ACE-related peptides, angiotensin II (AngII) and bradykinin (BK), and (3) the regulation of myocardial ACE by circulating Ang II, we used in vitro quantitative autoradiography to localize and assess ACE ([125I]351A), AngII receptor (125I[Sar1, IIe8]AngII), and BK receptor ([125I]Tyr8) binding densities in the rat myocardium." | 7.69 | Fibrosis and myocardial ACE: possible substrate and independence from circulating angiotensin II. ( Sun, Y; Weber, KT, 1994) |
| "Aldosterone is a mineralocorticoid hormone, as its main renal effect has been considered as electrolyte and water homeostasis in the distal tubule, thus maintaining blood pressure and extracellular fluid homeostasis through the activation of mineralocorticoid receptor (MR) in epithelial cells." | 6.61 | Role of Aldosterone in Renal Fibrosis. ( Che, RC; Shrestha, A; Zhang, AH, 2019) |
| "Aldosterone was discovered in 1953, and until the beginning of the 1960s, when spironolactone was developed, it was the focus of considerable interest among the scientific community." | 6.43 | [The role of aldosterone in the development of postinfarction fibrosis]. ( Cittadini, A; Monti, MG; Saccà, L; Serpico, R, 2005) |
| "Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass." | 6.42 | The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 6.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| "Aldosterone (Aldo) promotes proteoglycan synthesis in valve interstitial cells (VICs) from mitral valves via the mineralocorticoid receptor (MR)." | 5.72 | Sex-Related Signaling of Aldosterone/Mineralocorticoid Receptor Pathway in Calcific Aortic Stenosis. ( Álvarez de la Rosa, D; Álvarez, V; Arrieta, V; Fernández-Celis, A; Gainza, A; Garaikoetxea, M; García-Peña, A; Jaisser, F; Jover, E; López-Andrés, N; Martín-Nuñez, E; Matilla, L; Navarro, A; Sádaba, R, 2022) |
| "Aldosterone is a mediator of progressive renal disease, but the mechanisms for aldosterone-mediated renal impairment in mice with diabetes are not fully defined." | 5.56 | miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes. ( Gao, R; Ge, Q; Hu, J; Hu, R; Li, Q; Li, X; Luo, T; Ma, L; Peng, C; Qing, H; Wang, Y; Wang, Z; Wu, C; Xiao, X; Yang, J; Yang, S; Young, MJ, 2020) |
| "Aldosterone has an important role in the progression of renal fibrosis." | 5.51 | Aldosterone induces renal fibrosis by promoting HDAC1 expression, deacetylating H3K9 and inhibiting klotho transcription. ( Cheng, P; Gu, Y; Lai, L; Xue, J; Yan, M, 2019) |
| "Aldosterone treatment enhanced mRNA expression of genes associated with inflammation and fibrosis and stimulated differentiation of 3T3-L1 and brown preadipocytes." | 5.48 | Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma. ( Fan, C; Guan, M; Tan, W; Wang, L; Wei, Q; Wu, C; Wu, P; Xie, C; Xu, L; Xue, Y; Zhang, H; Zhang, J, 2018) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 5.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "Aldosterone plays a central role in the regulation of sodium and potassium homoeostasis by binding to the mineralocorticoid receptor and contributes to kidney and cardiovascular damage." | 5.43 | Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice. ( Enomoto, D; Higaki, J; Kukida, M; Miyoshi, K; Nagao, T; Okamura, H; Okura, T; Pei, Z; Tanino, A, 2016) |
| "Leptin is a newly described regulator of aldosterone synthesis that acts directly on adrenal glomerulosa cells to increase CYP11B2 expression and enhance aldosterone production via calcium-dependent mechanisms." | 5.42 | Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. ( Antonova, G; Belin de Chantemèle, EJ; Bollag, WB; Filosa, JA; Gomez-Sanchez, CE; Groenendyk, J; Huby, AC, 2015) |
| "Aldosterone-salt treatment induces not only hypertension but also extensive inflammation that contributes to fibrosis in the rat kidney." | 5.40 | Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats. ( Doi, S; Doi, T; Kohno, N; Masaki, T; Nakashima, A; Ueno, T; Yokoyama, Y, 2014) |
| "Hyperaldosteronism is associated with an increased prevalence of atrial fibrillation (AF)." | 5.38 | Aldosterone promotes atrial fibrillation. ( Allessie, MA; Böhm, M; Drautz, F; Hohl, M; Kazakow, A; Lipp, P; Müller, P; Münz, BM; Neuberger, HR; Reil, GH; Reil, JC; Selejan, S; Steendijk, P, 2012) |
| "Aldosterone (Aldo) is an important active hormone in the renin-angiotensin-aldosterone system and plays a vital role in the development of hypertension, heart failure and other cardiovascular diseases." | 5.38 | Endogenous aldosterone is involved in vascular calcification in rat. ( Cai, Y; Jia, LX; Qi, YF; Tang, CS; Wang, X; Wu, SY; Xiao, CS; Yu, YR, 2012) |
| "Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myocardial necrosis and fibrosis." | 5.36 | Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. ( Franco, M; Janicki, JS; Matsubara, BB; Matsubara, LS, 2010) |
| "Aldosterone promotes renal fibrosis via the mineralocorticoid receptor (MR), thus contributing to hypertension-induced nephropathy." | 5.35 | Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. ( Camp, JR; Cavallari, LH; Fashingbauer, LA; Geenen, DL; King, ST, 2008) |
| "Aldosterone plays a detrimental role in the pathology of chronic heart failure." | 5.35 | Comparison of the effects of intrapericardial and intravenous aldosterone infusions on left ventricular fibrosis in rats. ( Bitsch, N; Essen, Hv; Hermans, JJ; Minnaard-Huiban, M; Smits, JF, 2008) |
| "Telmisartan was administered to renovascular hypertensive rats at either a high dose (5 mg per kg per day; high-T group) or a low dose (0." | 5.35 | Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. ( Hongo, K; Kawai, M; Komukai, K; Mochizuki, S; Morimoto, S; Nagai, M; Seki, S; Taniguchi, I; Yoshimura, M, 2009) |
| "Reversal of cardiac fibrosis is a major determinant of the salutary effects of mineralocorticoid receptor antagonists in heart failure." | 5.35 | Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone. ( Beugels, IP; Cohuet, GM; de Gooyer, ME; Emmen, JM; Hermans, JJ; Hilbers, PA; Minnaard-Huiban, M; Ottenheijm, HC; Pieterse, K; Plate, R; Roumen, L; Ruijters, E; Smits, JF; van Essen, H, 2008) |
| "Hyperaldosteronism is associated with hypertension, cardiovascular fibrosis, and electrolyte disturbances, including hypomagnesemia." | 5.35 | Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. ( Montezano, AC; Paravicini, T; Sontia, B; Tabet, F; Touyz, RM, 2008) |
| "Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI." | 5.33 | Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005) |
| "Uremia was associated to myocardial hypertrophy, fibrosis and apoptosis." | 5.33 | Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone. ( Amato, D; Avila-Díaz, M; Foyo-Niembro, E; Paniagua, R; Ramirez-San-Juan, E; Rodríguez-Ayala, E, 2006) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 5.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "Increased bioavailability of reactive oxygen species (ROS) has been implicated in the pathogenesis of mineralocorticoid hypertension." | 5.32 | NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. ( Park, JB; Park, MY; Park, YM; Suh, YL, 2004) |
| "Aldosterone promotes collagen synthesis and structural remodeling of the heart." | 5.32 | Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. ( Colucci, WS; Kerstetter, DL; Ooi, H; Sam, F; Singh, K; Singh, M; Xie, Z, 2004) |
| "Aldosterone levels were not significantly elevated, suggesting direct proliferative effects of Ang II." | 5.30 | Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. ( Gray, GA; Kenyon, CJ; McEwan, PE; Sherry, L; Webb, DJ, 1998) |
| "Cardiac fibrosis is linked to aldosterone-induced hypertension, but the effects on in vivo left ventricular (LV) function are not established." | 5.30 | In vivo left ventricular function and collagen expression in aldosterone/salt-induced hypertension. ( Charlemagne, D; Delcayre, C; Lechat, P; Mougenot, N; Ramirez-Gil, JF; Robert, V; Trouve, P; Wassef, M, 1998) |
| "Fibrosis was quantified by slot blots of collagen I and III mRNA levels and videomorphometry of Sirius red-stained collagen." | 5.30 | Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. ( Delcayre, C; Heymes, C; Robert, V; Sabri, A; Silvestre, JS; Swynghedauw, B, 1999) |
| "The reactive fibrosis is thought to be related to MC excess, while cell loss and microscopic scarring may be secondary to enhanced potassium excretion or a cytotoxic effect of aldosterone." | 5.29 | Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. ( Campbell, SE; Janicki, JS; Matsubara, BB; Weber, KT, 1993) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 5.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| "Patients with SRV treated with eplerenone showed an improvement of an altered baseline CTB profile suggesting that reduction of myocardial fibrosis might be a therapeutic target in these patients." | 5.17 | Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study. ( Casaldàliga, J; Dos, L; Estruch, M; Ferreira-González, I; García-Dorado, D; Marsal, JR; Mas, A; Ordóñez-Llanos, J; Pijuan, A; Pons-Lladó, G; Pujadas, S; Serra, R; Subirana, M, 2013) |
| "Studies in animals and humans show that increased tissue acidity raises the renal levels of endothelin, angiotensin II, aldosterone, and ammoniagenesis, thereby worsening renal fibrosis and causing progression of CKD." | 4.98 | Retarding progression of chronic kidney disease: use of modalities that counter acid retention. ( Kraut, JA; Madias, NE, 2018) |
| " Hyperaldosteronism due to klotho deficiency results in vascular calcification, which can be mitigated by spironolactone treatment." | 4.90 | Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. ( Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Kienreich, K; Kraigher-Krainer, E; März, W; Mrak, P; Pieske, B; Pilz, S; Ritz, E; Rus-Machan, J; Tomaschitz, A; Toplak, H; Verheyen, N, 2014) |
| " Angiotensin II and aldosterone often collaborate in pathological situations to induce hypertrophy of cardiomyocytes, vascular inflammation, perivascular and interstitial fibrosis, and microvascular rarefaction." | 4.89 | Aldosterone mediates cardiac fibrosis in the setting of hypertension. ( Azibani, F; Chatziantoniou, C; Delcayre, C; Fazal, L; Samuel, JL, 2013) |
| " Studies using gene-modified mice deficient in Nox2 activity indicate that Nox2 activation contributes to angiotensin II-induced cardiomyocyte hypertrophy, atrial fibrillation, and the development of interstitial fibrosis but may also positively modulate physiological excitation-contraction coupling." | 4.89 | NADPH oxidases in heart failure: poachers or gamekeepers? ( Ghigo, A; Hirsch, E; Perino, A; Shah, AM; Zhang, M, 2013) |
| "In experimental models where chronic inappropriate (relative to sodium intake and intravascular volume) elevations in circulating mineralocorticoids (aldosterone or deoxycorticosterone) are created, a reactive fibrosis with vascular remodeling is observed in systemic organs and the heart." | 4.80 | Extra-adrenal mineralocorticoids and cardiovascular tissue. ( Ganjam, VK; Joseph, J; Slight, SH; Weber, KT, 1999) |
| "Both aldosterone and arginine vasopressin (AVP) are produced in the heart and may participate in cardiac fibrosis." | 4.12 | Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction. ( Gao, X; Li, J; Lu, G; Peng, L; Zhai, YS, 2022) |
| "Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis." | 3.85 | Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017) |
| " UUO induced monocyte renal infiltration, tubular cell apoptosis, tubular atrophy, interstitial fibrosis and overexpression of TGFβ, Renin mRNA (RENmRNA), increase of Renin, Angiotensin II (AII) and aldosterone serum levels." | 3.83 | Mesenchymal Stromal Cells Prevent Renal Fibrosis in a Rat Model of Unilateral Ureteral Obstruction by Suppressing the Renin-Angiotensin System via HuR. ( Albertini, R; Avanzini, MA; Bedino, G; Corradetti, V; Dal Canton, A; Esposito, P; Gregorini, M; Ingo, D; Libetta, C; Mantelli, M; Milanesi, S; Pattonieri, EF; Peressini, S; Rampino, T; Rocca, C; Serpieri, N; Valsania, T, 2016) |
| " Levels of norepinephrine, renin and aldosterone in plasma, norepinephrine, angiotensin II, aldosterone, interleukin-6 and high sensitivity C-reactive protein in atrial tissue were elevated, and atrial interstitial fibrosis was enhanced by RI, which were attenuated by RDN." | 3.81 | Renal denervation suppresses atrial fibrillation in a model of renal impairment. ( Chen, FK; Chen, XP; Guo, HY; Li, J; Li, YG; Liang, Z; Lin, K; Liu, LF; Shan, ZL; Shi, XM; Wang, YT, 2015) |
| " This study suggests that telmisartan (TEL) can inhibit myocardial fibrosis of hypertensive left ventricular hypertrophy (LVH) through the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway." | 3.80 | Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway. ( Guan, G; Ma, A; Shao, L; Tian, G; Wang, J; Wang, Y; Zhang, Y, 2014) |
| "The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood." | 3.80 | Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014) |
| " We evaluated the efficacy of MR antagonism by spironolactone in two experimental PH models; mouse chronic hypoxia-induced PH (prevention model) and rat monocrotaline-induced PH (prevention and treatment models)." | 3.79 | Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. ( Fanburg, BL; Hill, NS; Jaffe, IZ; Preston, IR; Sagliani, KD; Warburton, RR, 2013) |
| " The authors hypothesized that reduction in aldosterone production in diabetes by amlodipine or aliskiren improves diabetic kidney disease by attenuating renal oxidative stress and fibrosis." | 3.79 | Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. ( Matavelli, LC; Siragy, HM, 2013) |
| "To investigate the in vivo and in vitro protective effects of pentamethylquercetin (PMQ), a member of polymethoxy flavonoids (PMFs), on cardiac hypertrophy." | 3.78 | In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. ( Chen, L; Chen, Y; Han, Y; He, T; Jin, MW; Yang, WQ, 2012) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 3.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "Hypertension was induced by continuous angiotensin II (Ang II) infusion via osmotic mini-pumps over 4 weeks." | 3.77 | Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage. ( Cordasic, N; Daniel, C; Hartner, A; Heusinger-Ribeiro, J; Hilgers, KF; Klanke, B; Knier, B; Veelken, R, 2011) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 3.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR." | 3.74 | [Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008) |
| " To elucidate its significance for myocardial fibrosis in the hypertensive heart, we used a mouse model with infusion of angiotensin II and examined results by histology, immunohistochemistry, in situ hybridization, and quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)." | 3.74 | Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. ( Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T, 2007) |
| "Long-term administration of angiotensin II causes myocardial loss and cardiac fibrosis." | 3.73 | Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-beta1 in the heart. ( Aizawa, T; Ishizaka, N; Iso-o, N; Mori, I; Nagai, R; Noiri, E; Ohno, M; Saito, K; Sata, M, 2005) |
| "We recently demonstrated that both lisinopril and candesartan, an angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker, respectively, attenuate pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori (WBN/Kob) rats." | 3.73 | Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. ( Ando, T; Itoh, M; Joh, T; Kuno, A; Masuda, K; Nakamura, S; Nomura, T; Ogawa, K; Ohara, H; Okamoto, T; Shirai, T; Tang, M; Yamada, T, 2005) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 3.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| " Since chronic inhibition of nitric oxide (NO) synthase with N(omega)-nitro-L-arginine methyl ester (L-NAME) induces systemic hypertension associated with cardiovascular inflammation and remodeling, we examined the potential role of aldosterone in this process using eplerenone, a selective aldosterone receptor antagonist." | 3.73 | The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. ( Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L, 2006) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 3.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| "We evaluated the role of aldosterone as a mediator of renal inflammation and fibrosis in a rat model of aldosterone/salt hypertension using the selective aldosterone blocker, eplerenone." | 3.72 | Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. ( Blasi, ER; Blomme, EA; McMahon, EG; Polly, ML; Rocha, R; Rudolph, AE, 2003) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 3.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "In congestive heart failure, angiotensin-converting enzyme inhibitors (ACEIs) may prevent cardiac fibrosis via interaction with both angiotensin II and endothelin-1, which enhance myocardial collagen synthesis." | 3.72 | Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. ( Dohke, T; Eguchi, Y; Fujii, M; Horie, M; Isono, T; Matsumoto, T; Ohnishi, M; Takayama, T; Tsutamoto, T; Wada, A; Yamamoto, T, 2004) |
| "These results show that in old normotensive rats, spironolactone can markedly prevent cardiac and, to a lesser extent, arterial fibrosis and improve arterial stiffness, despite a lack of hypotensive effect." | 3.71 | Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. ( Benetos, A; Labat, C; Lacolley, P; Ledudal, K; Lucet, B; Safar, ME, 2001) |
| " The effect of the angiotensin II type 1 receptor antagonist, losartan (10 mg x kg(-1) x d(-1))on aldosterone-induced cardiac hypertrophy was also studied." | 3.71 | Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. ( Demura, M; Mabuchi, H; Takeda, Y; Usukura, M; Yoneda, T, 2002) |
| "Increased endothelin-1 (ET-1) or aldosterone may be associated with promotion of cardiovascular hypertrophy and fibrosis." | 3.71 | Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. ( Park, JB; Schiffrin, EL, 2002) |
| "Chronic administration of either angiotensin II (Ang II) or aldosterone (ALDO) leads to myocardial fibrosis." | 3.70 | Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. ( Ramires, FJ; Sun, Y; Weber, KT, 1998) |
| " This increase is mediated primarily by cardiac angiotensin II via AT1-subtype receptor and may be involved in post-MI ventricular fibrosis and in control of tissue norepinephrine concentration." | 3.70 | Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. ( Aupetit-Faisant, B; Carayon, A; Delcayre, C; Heymes, C; Oubénaïssa, A; Robert, V; Silvestre, JS; Swynghedauw, B, 1999) |
| "Myocardial fibrosis, associated with increased expression of angiotensin converting enzyme (ACE) and bradykinin (BK) receptor binding at sites of tissue repair, accompanies chronic elevations in circulating angiotensin II (AngII) and/or aldosterone (ALDO) that simulate chronic cardiac failure." | 3.69 | Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. ( Ramires, FJ; Sun, Y; Weber, KT, 1997) |
| "In order to determine the relation between myocardial fibrosis and (1) angiotensin converting enzyme (ACE) binding density, (2) receptor binding of ACE-related peptides, angiotensin II (AngII) and bradykinin (BK), and (3) the regulation of myocardial ACE by circulating Ang II, we used in vitro quantitative autoradiography to localize and assess ACE ([125I]351A), AngII receptor (125I[Sar1, IIe8]AngII), and BK receptor ([125I]Tyr8) binding densities in the rat myocardium." | 3.69 | Fibrosis and myocardial ACE: possible substrate and independence from circulating angiotensin II. ( Sun, Y; Weber, KT, 1994) |
| " Even though the angiotensin converting enzyme inhibitor captopril was previously found to attenuate this interstitial and perivascular fibrosis, the relative importance of arterial and ventricular systolic pressures versus circulating angiotensin II (AII) and aldosterone (AL) in promoting hypertrophy and collagen accumulation in renovascular hypertension is uncertain." | 3.68 | Remodeling of the rat right and left ventricles in experimental hypertension. ( Brilla, CG; Janicki, JS; Pick, R; Tan, LB; Weber, KT, 1990) |
| "Primary aldosteronism (PA) is a pathological condition characterized by an excessive aldosterone secretion; once thought to be rare, PA is now recognized as the most common cause of secondary hypertension." | 2.82 | Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight. ( Arata, S; Bioletto, F; Bollati, M; Ghigo, E; Lopez, C; Maccario, M; Parasiliti-Caprino, M; Ponzetto, F; Procopio, M, 2022) |
| "Primary aldosteronism is the most frequent cause of secondary hypertension and is associated with more prominent left ventricular hypertrophy and increased myocardial fibrosis." | 2.77 | Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. ( Chang, HW; Chueh, SC; Ho, YL; Lee, HH; Lee, JK; Lin, CY; Lin, LC; Lin, YH; Liu, YC; Lo, MT; Wu, KD; Wu, VC; Wu, XM, 2012) |
| "Aldosterone is a mineralocorticoid hormone, as its main renal effect has been considered as electrolyte and water homeostasis in the distal tubule, thus maintaining blood pressure and extracellular fluid homeostasis through the activation of mineralocorticoid receptor (MR) in epithelial cells." | 2.61 | Role of Aldosterone in Renal Fibrosis. ( Che, RC; Shrestha, A; Zhang, AH, 2019) |
| "Fibrosis is a fundamental component of the adverse structural remodeling of myocardium present in the failing heart." | 2.47 | Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. ( Ahokas, RA; Bhattacharya, SK; Gandhi, MS; Gerling, IC; Kamalov, G; Shahbaz, AU; Sun, Y; Weber, KT, 2011) |
| "The prevalence of hyperaldosteronism is increased among patients with obesity or resistant hypertension." | 2.47 | This is not Dr. Conn's aldosterone anymore. ( Brown, NJ, 2011) |
| "Primary aldosteronism is the most common cause of mineralocorticoid-induced hypertension, and MR antagonism offers the best prospect for achieving therapeutic goals." | 2.44 | Mineralocorticoid antagonism and cardiac hypertrophy. ( Nagata, K, 2008) |
| "Inflammation is associated with fibrosis." | 2.43 | [PPARs and fibrosis]. ( Kurabayashi, M, 2005) |
| "Aldosterone was discovered in 1953, and until the beginning of the 1960s, when spironolactone was developed, it was the focus of considerable interest among the scientific community." | 2.43 | [The role of aldosterone in the development of postinfarction fibrosis]. ( Cittadini, A; Monti, MG; Saccà, L; Serpico, R, 2005) |
| "Aldosterone has direct effects on the vasculature and has been associated with vascular smooth muscle cell hypertrophy, endothelial dysfunction, cardiac fibrosis, proteinuria, and renal vascular injury." | 2.42 | Aldosterone: a risk factor for vascular disease. ( Fritsch Neves, M; Schiffrin, EL, 2003) |
| "Heart failure is a major health problem of epidemic proportions." | 2.42 | Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. ( Ahokas, RA; Gerling, IC; Guntaka, RV; Kiani, MF; Postlethwaite, AE; Sun, Y; Warrington, KJ; Weber, KT, 2003) |
| "Anti-aldosterone drugs have been clinically reported to be useful for their organ-protecting effects." | 2.42 | Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. ( Saruta, T; Sato, A, 2004) |
| "Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass." | 2.42 | The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004) |
| "Aldosterone has several deleterious properties." | 2.41 | Aldosterone: cardiovascular assault. ( Struthers, AD, 2002) |
| "Aldosterone production plays an important role in the remodeling of the heart." | 2.41 | Molecular mechanisms of myocardial remodeling. The role of aldosterone. ( Delcayre, C; Swynghedauw, B, 2002) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 2.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| "Reactive fibrosis is associated with elevations in plasma aldosterone concentrations that are inappropriate relative to dietary sodium intake." | 2.38 | Factors associated with reactive and reparative fibrosis of the myocardium. ( Brilla, CG; Weber, KT, 1992) |
| "Aldosterone has been assumed to be one of aggravating factors in diabetic kidney disease (DKD)." | 1.91 | Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess. ( Handa, T; Ikushima, A; Inoue, Y; Ishii, A; Ishimura, T; Kato, Y; Minamino, N; Mori, KP; Mukoyama, M; Nishio, H; Ohno, S; Sugioka, S; Yamada, H; Yanagita, M; Yokoi, H, 2023) |
| "Renal fibrosis is an inevitable process in the progression of chronic kidney disease (CKD)." | 1.91 | Esaxerenone Inhibits Renal Angiogenesis and Endothelial-Mesenchymal Transition via the VEGFA and TGF-β1 Pathways in Aldosterone-Infused Mice. ( Chang, J; Chang, Y; Fan, L; Gao, X; Liu, Z; Shimosawa, T; Xu, Q; Yang, F; Zhang, C, 2023) |
| "Aldosterone (Aldo) promotes proteoglycan synthesis in valve interstitial cells (VICs) from mitral valves via the mineralocorticoid receptor (MR)." | 1.72 | Sex-Related Signaling of Aldosterone/Mineralocorticoid Receptor Pathway in Calcific Aortic Stenosis. ( Álvarez de la Rosa, D; Álvarez, V; Arrieta, V; Fernández-Celis, A; Gainza, A; Garaikoetxea, M; García-Peña, A; Jaisser, F; Jover, E; López-Andrés, N; Martín-Nuñez, E; Matilla, L; Navarro, A; Sádaba, R, 2022) |
| "Patients with diabetic kidney disease excreted more tetrahydroaldosterone than the control group reaching significance in men." | 1.72 | Increased glucocorticoid metabolism in diabetic kidney disease. ( Ackermann, D; Bochud, M; Burnier, M; Dick, B; Ehret, G; Gennari-Moser, C; Guessous, I; Jamin, H; Klossner, R; Martin, PY; Mohaupt, MG; Paccaud, F; Pechère-Bertschi, A; Ponte, B; Pruijm, M; Vogt, B, 2022) |
| "Renal fibrosis is the inevitable pathway of the progression of chronic kidney disease to end-stage renal disease, which manifests as progressive glomerulosclerosis and renal interstitial fibrosis." | 1.72 | Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone. ( Chang, Y; Gao, X; Han, Y; Hao, J; Liang, L; Qiang, P; Shimosawa, T; Xian, Y; Xiong, Y; Xu, Q; Yang, F, 2022) |
| "Aldosterone (Aldo) promotes fibrosis in myocardium, and MR (mineralocorticoid receptor) antagonists (MRAs) improve cardiac function by decreasing cardiac fibrosis." | 1.56 | A New Role for the Aldosterone/Mineralocorticoid Receptor Pathway in the Development of Mitral Valve Prolapse. ( Alvarez de la Rosa, D; Alvarez, V; Arrieta, V; Bonnard, B; Fernández-Celis, A; Gainza, A; Garcia-Peña, A; Ibarrola, J; Jaisser, F; López-Andrés, N; Matilla, L; Navarro, A; Rossignol, P; Sádaba, R, 2020) |
| "Aldosterone is a mediator of progressive renal disease, but the mechanisms for aldosterone-mediated renal impairment in mice with diabetes are not fully defined." | 1.56 | miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes. ( Gao, R; Ge, Q; Hu, J; Hu, R; Li, Q; Li, X; Luo, T; Ma, L; Peng, C; Qing, H; Wang, Y; Wang, Z; Wu, C; Xiao, X; Yang, J; Yang, S; Young, MJ, 2020) |
| "Aldosterone has an important role in the progression of renal fibrosis." | 1.51 | Aldosterone induces renal fibrosis by promoting HDAC1 expression, deacetylating H3K9 and inhibiting klotho transcription. ( Cheng, P; Gu, Y; Lai, L; Xue, J; Yan, M, 2019) |
| "Objective- Pulmonary arterial hypertension is characterized by progressive pulmonary vascular remodeling and persistently elevated mean pulmonary artery pressures and pulmonary vascular resistance." | 1.51 | Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. ( Huang, Y; Jing, ZC; Li, J; Liu, YW; Meng, J; Pan, HZ; Wang, PH; Xiang, L; Yang, J; Zhang, H; Zhang, XL, 2019) |
| "Aldosterone has been proved a risk factor of fibrosis and inflammation." | 1.51 | Aldosterone induced up-expression of ICAM-1 and ET-1 in pancreatic islet endothelium may associate with progression of T2D. ( Chen, L; Cui, C; Guo, X; He, Q; Hou, X; Hu, H; Liu, F; Qin, J; Song, J; Wang, J; Yan, F, 2019) |
| "Aldosterone treatment enhanced mRNA expression of genes associated with inflammation and fibrosis and stimulated differentiation of 3T3-L1 and brown preadipocytes." | 1.48 | Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma. ( Fan, C; Guan, M; Tan, W; Wang, L; Wei, Q; Wu, C; Wu, P; Xie, C; Xu, L; Xue, Y; Zhang, H; Zhang, J, 2018) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 1.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "Cardiac fibrosis is characterized by an excessive accumulation of extracellular matrix components, including collagens." | 1.46 | Differential Proteomics Identifies Reticulocalbin-3 as a Novel Negative Mediator of Collagen Production in Human Cardiac Fibroblasts. ( Fernández-Celis, A; Fernández-Irigoyen, J; Ibarrola, J; Jaisser, F; López-Andrés, N; Martínez-Martínez, E; Rossignol, P; Santamaria, E, 2017) |
| "HFpEF mice developed hypertension, left ventricular hypertrophy, and diastolic dysfunction and had higher myocardial natriuretic peptide expression." | 1.43 | Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. ( Aprahamian, T; Fuster, JJ; Hulsmans, M; Li, S; Nahrendorf, M; Sam, F; Scherer, PE; Valero-Muñoz, M; Wilson, RM, 2016) |
| "In patients with primary aldosteronism, plasma TIMP-1 was correlated with 24-hour urinary aldosterone, left ventricular mass, and impairment of left ventricular diastolic function." | 1.43 | Aldosterone Induces Tissue Inhibitor of Metalloproteinases-1 Expression and Further Contributes to Collagen Accumulation: From Clinical to Bench Studies. ( Chang, YY; Chen, MF; Chen, YH; Chou, CH; Ho, YL; Hung, CS; Liao, CW; Lin, YH; Lin, YT; Su, MJ; Wu, KD; Wu, VC; Wu, XM, 2016) |
| "Aldosterone has been recognized as a risk factor for the development of chronic kidney disease (CKD)." | 1.43 | Epidermal growth factor receptor signaling mediates aldosterone-induced profibrotic responses in kidney. ( Ding, W; Gu, Y; Niu, J; Qiao, Z; Sheng, L; Yang, M; Zhang, M, 2016) |
| "Aldosterone plays a central role in the regulation of sodium and potassium homoeostasis by binding to the mineralocorticoid receptor and contributes to kidney and cardiovascular damage." | 1.43 | Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice. ( Enomoto, D; Higaki, J; Kukida, M; Miyoshi, K; Nagao, T; Okamura, H; Okura, T; Pei, Z; Tanino, A, 2016) |
| "Leptin is a newly described regulator of aldosterone synthesis that acts directly on adrenal glomerulosa cells to increase CYP11B2 expression and enhance aldosterone production via calcium-dependent mechanisms." | 1.42 | Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. ( Antonova, G; Belin de Chantemèle, EJ; Bollag, WB; Filosa, JA; Gomez-Sanchez, CE; Groenendyk, J; Huby, AC, 2015) |
| "Hypertension is accompanied by high or low circulating AngII levels and cardiac/renal injury." | 1.40 | Autocrine and paracrine function of Angiotensin 1-7 in tissue repair during hypertension. ( Chen, Y; Liu, C; Liu, H; Meng, W; Sun, Y; Zhao, T; Zhao, W, 2014) |
| "Aldosterone-salt treatment induces not only hypertension but also extensive inflammation that contributes to fibrosis in the rat kidney." | 1.40 | Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats. ( Doi, S; Doi, T; Kohno, N; Masaki, T; Nakashima, A; Ueno, T; Yokoyama, Y, 2014) |
| "Patients with primary aldosteronism are associated with increased myocardial fibrosis." | 1.40 | Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans. ( Chang, YY; Chen, YH; Chou, CH; Ho, YL; Hsieh, FJ; Hung, CS; Lin, YH; Tzeng, YL; Wu, KD; Wu, VC; Wu, XM, 2014) |
| "Hyperaldosteronism is associated with an increased prevalence of atrial fibrillation (AF)." | 1.38 | Aldosterone promotes atrial fibrillation. ( Allessie, MA; Böhm, M; Drautz, F; Hohl, M; Kazakow, A; Lipp, P; Müller, P; Münz, BM; Neuberger, HR; Reil, GH; Reil, JC; Selejan, S; Steendijk, P, 2012) |
| "Aldosterone (Aldo) is an important active hormone in the renin-angiotensin-aldosterone system and plays a vital role in the development of hypertension, heart failure and other cardiovascular diseases." | 1.38 | Endogenous aldosterone is involved in vascular calcification in rat. ( Cai, Y; Jia, LX; Qi, YF; Tang, CS; Wang, X; Wu, SY; Xiao, CS; Yu, YR, 2012) |
| "Hyperaldosteronism combined with hypertension favored the macrophage infiltration (CD68(+) cells) in heart, and enhanced the mRNA level of monocyte chemoattractant protein 1, osteopontin, and galectin 3." | 1.38 | Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. ( Azibani, F; Benard, L; Carrier, L; Chatziantoniou, C; Delcayre, C; Fazal, L; Launay, JM; Merval, R; Polidano, E; Samuel, JL; Schlossarek, S; Tournoux, F, 2012) |
| "Hypertension is characterized by left ventricular (LV) hypertrophy (LVH)." | 1.38 | Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure. ( Baid, S; Garcia, AG; Heo, J; Murthy, NR; Ouchi, N; Sam, F; Wilson, RM, 2012) |
| "Treatment with spironolactone was evaluated to prove mineralocorticoid mediation." | 1.37 | Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression. ( Ballesteros, S; Cachofeiro, V; de las Heras, N; Delgado, C; Hintze, T; Lahera, V; Martín-Fernández, B; Miana, M; Song, S, 2011) |
| "Spironolactone treatment reversed all the above effects." | 1.37 | A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. ( Cachofeiro, V; Díez, J; Fortuno, MA; Lahera, V; López-Andrés, N; Martin-Fernandez, B; Rossignol, P; Zannad, F, 2011) |
| "Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myocardial necrosis and fibrosis." | 1.36 | Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. ( Franco, M; Janicki, JS; Matsubara, BB; Matsubara, LS, 2010) |
| "Aldosterone has been correlated with increased oxidative stress, endothelial inflammation, and fibrosis, particularly in patients with heart disease." | 1.36 | Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. ( Becerra, E; Carvajal, CA; Fardella, CE; García, L; Jalil, J; Lavandero, S; Mellado, R; Mosso, L; Ocaranza, MP; Solis, M; Stehr, CB, 2010) |
| "Aldosterone promotes renal fibrosis via the mineralocorticoid receptor (MR), thus contributing to hypertension-induced nephropathy." | 1.35 | Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. ( Camp, JR; Cavallari, LH; Fashingbauer, LA; Geenen, DL; King, ST, 2008) |
| "Aldosterone plays a detrimental role in the pathology of chronic heart failure." | 1.35 | Comparison of the effects of intrapericardial and intravenous aldosterone infusions on left ventricular fibrosis in rats. ( Bitsch, N; Essen, Hv; Hermans, JJ; Minnaard-Huiban, M; Smits, JF, 2008) |
| "Aldosterone plays a crucial role in renal fibrosis by inducing mesangial cell proliferation and promoting collagen synthesis in renal fibroblasts." | 1.35 | Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules. ( Liu, A; Liu, X; Xu, G, 2008) |
| "Telmisartan was administered to renovascular hypertensive rats at either a high dose (5 mg per kg per day; high-T group) or a low dose (0." | 1.35 | Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. ( Hongo, K; Kawai, M; Komukai, K; Mochizuki, S; Morimoto, S; Nagai, M; Seki, S; Taniguchi, I; Yoshimura, M, 2009) |
| "The aldosterone-induced increase in renal TGFbeta1 and PCNA was significantly prevented by treatment with DMA." | 1.35 | The role of Na+-H+ exchanger isoform 1 in aldosterone-induced glomerulosclerosis in vivo. ( Chen, J; Gu, Y; Lin, S; Liu, S; You, L; Zhang, M, 2009) |
| "Reversal of cardiac fibrosis is a major determinant of the salutary effects of mineralocorticoid receptor antagonists in heart failure." | 1.35 | Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone. ( Beugels, IP; Cohuet, GM; de Gooyer, ME; Emmen, JM; Hermans, JJ; Hilbers, PA; Minnaard-Huiban, M; Ottenheijm, HC; Pieterse, K; Plate, R; Roumen, L; Ruijters, E; Smits, JF; van Essen, H, 2008) |
| "Hyperaldosteronism is associated with hypertension, cardiovascular fibrosis, and electrolyte disturbances, including hypomagnesemia." | 1.35 | Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. ( Montezano, AC; Paravicini, T; Sontia, B; Tabet, F; Touyz, RM, 2008) |
| "Aldosterone plays a key role in the pathogenesis of Ang II-induced organ damage." | 1.33 | Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. ( Al-Saadi, N; Dechend, R; Fiebeler, A; Hilfenhaus, G; Jeng, AY; Luft, FC; Maser-Gluth, C; Meiners, S; Muller, DN; Nussberger, J; Rong, S; Shagdarsuren, E; Webb, RL; Wellner, M, 2005) |
| "Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI." | 1.33 | Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005) |
| "The GK rats developed hypertension, cardiac hypertrophy and overexpression of cardiac natriuretic peptides and profibrotic connective tissue growth factor compared to nondiabetic Wistar rats." | 1.33 | Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. ( Bäcklund, T; Cheng, ZJ; Eriksson, A; Finckenberg, P; Grönholm, T; Laine, M; Mervaala, E; Palojoki, E; Tikkanen, I; Vuolteenaho, O, 2005) |
| "Uremia was associated to myocardial hypertrophy, fibrosis and apoptosis." | 1.33 | Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone. ( Amato, D; Avila-Díaz, M; Foyo-Niembro, E; Paniagua, R; Ramirez-San-Juan, E; Rodríguez-Ayala, E, 2006) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 1.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "It indicates that portal hypertension is an important factor in the genesis of cardiac dysfunction." | 1.32 | Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. ( Bandopadhyay, K; Biswas, PK; Das, D; Das, TK; Dasgupta, S; De, BK; Guru, S; Majumdar, D; Mandal, SK; Ray, S, 2003) |
| "Increased bioavailability of reactive oxygen species (ROS) has been implicated in the pathogenesis of mineralocorticoid hypertension." | 1.32 | NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. ( Park, JB; Park, MY; Park, YM; Suh, YL, 2004) |
| "Aldosterone promotes collagen synthesis and structural remodeling of the heart." | 1.32 | Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. ( Colucci, WS; Kerstetter, DL; Ooi, H; Sam, F; Singh, K; Singh, M; Xie, Z, 2004) |
| "In patients with untreated hypertension, there is evidence of increased collagen synthesis, degradation, and inhibition of degradation resulting in fibrosis." | 1.31 | TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. ( Dunn, FG; Lindsay, MM; Maxwell, P, 2002) |
| "Aldosterone promotes nephrosclerosis in several rat models, whereas aldosterone receptor antagonism blunts the effect of activation of the renin-angiotensin-aldosterone system (RAAS) on nephrosclerosis, independent of effects on blood pressure." | 1.31 | Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. ( Brown, NJ; Donnert, E; Fogo, AB; Freeman, M; Ma, L; Nakamura, I; Nakamura, S; Vaughan, DE, 2000) |
| "Aldosterone levels were not significantly elevated, suggesting direct proliferative effects of Ang II." | 1.30 | Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. ( Gray, GA; Kenyon, CJ; McEwan, PE; Sherry, L; Webb, DJ, 1998) |
| "Cardiac fibrosis is linked to aldosterone-induced hypertension, but the effects on in vivo left ventricular (LV) function are not established." | 1.30 | In vivo left ventricular function and collagen expression in aldosterone/salt-induced hypertension. ( Charlemagne, D; Delcayre, C; Lechat, P; Mougenot, N; Ramirez-Gil, JF; Robert, V; Trouve, P; Wassef, M, 1998) |
| "Fibrosis was quantified by slot blots of collagen I and III mRNA levels and videomorphometry of Sirius red-stained collagen." | 1.30 | Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. ( Delcayre, C; Heymes, C; Robert, V; Sabri, A; Silvestre, JS; Swynghedauw, B, 1999) |
| "The reactive fibrosis is thought to be related to MC excess, while cell loss and microscopic scarring may be secondary to enhanced potassium excretion or a cytotoxic effect of aldosterone." | 1.29 | Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. ( Campbell, SE; Janicki, JS; Matsubara, BB; Weber, KT, 1993) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 1.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| "Spironolactone was able largely to prevent the perivascular/interstitial fibrosis and scarring in either model irrespective of the development of left ventricular hypertrophy and arterial hypertension." | 1.28 | Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. ( Brilla, CG; Weber, KT, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (8.93) | 18.2507 |
| 2000's | 107 (38.21) | 29.6817 |
| 2010's | 118 (42.14) | 24.3611 |
| 2020's | 30 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Schreier, B | 2 |
| Zipprich, A | 1 |
| Uhlenhaut, H | 1 |
| Gekle, M | 2 |
| Wu, Y | 1 |
| Yang, H | 2 |
| Xu, S | 1 |
| Cheng, M | 1 |
| Gu, J | 1 |
| Zhang, W | 1 |
| Liu, S | 3 |
| Zhang, M | 5 |
| Howard, ZM | 1 |
| Rastogi, N | 1 |
| Lowe, J | 1 |
| Hauck, JS | 1 |
| Ingale, P | 1 |
| Gomatam, C | 1 |
| Gomez-Sanchez, CE | 2 |
| Gomez-Sanchez, EP | 1 |
| Bansal, SS | 1 |
| Rafael-Fortney, JA | 1 |
| Cannavo, A | 1 |
| Liccardo, D | 1 |
| Gelzo, M | 1 |
| Amato, F | 1 |
| Gentile, I | 1 |
| Pinchera, B | 1 |
| Femminella, GD | 1 |
| Parrella, R | 1 |
| DE Rosa, A | 1 |
| Gambino, G | 1 |
| Marzano, F | 1 |
| Ferrara, N | 1 |
| Paolocci, N | 1 |
| Rengo, G | 1 |
| Castaldo, G | 1 |
| Matilla, L | 2 |
| Jover, E | 1 |
| Garaikoetxea, M | 1 |
| Martín-Nuñez, E | 1 |
| Arrieta, V | 2 |
| García-Peña, A | 2 |
| Navarro, A | 2 |
| Fernández-Celis, A | 4 |
| Gainza, A | 2 |
| Álvarez, V | 2 |
| Álvarez de la Rosa, D | 2 |
| Sádaba, R | 2 |
| Jaisser, F | 10 |
| López-Andrés, N | 7 |
| Tsai, CH | 1 |
| Liao, CW | 5 |
| Wu, XM | 7 |
| Chen, ZW | 2 |
| Pan, CT | 1 |
| Chang, YY | 6 |
| Lee, BC | 1 |
| Shun, CT | 2 |
| Wen, WF | 2 |
| Chou, CH | 5 |
| Wu, VC | 7 |
| Hung, CS | 6 |
| Lin, YH | 7 |
| Bioletto, F | 1 |
| Bollati, M | 1 |
| Lopez, C | 1 |
| Arata, S | 1 |
| Procopio, M | 1 |
| Ponzetto, F | 1 |
| Ghigo, E | 1 |
| Maccario, M | 1 |
| Parasiliti-Caprino, M | 1 |
| Ackermann, D | 1 |
| Vogt, B | 2 |
| Bochud, M | 1 |
| Burnier, M | 1 |
| Martin, PY | 1 |
| Paccaud, F | 1 |
| Ehret, G | 1 |
| Guessous, I | 1 |
| Ponte, B | 1 |
| Pruijm, M | 1 |
| Pechère-Bertschi, A | 1 |
| Jamin, H | 1 |
| Klossner, R | 1 |
| Dick, B | 2 |
| Mohaupt, MG | 1 |
| Gennari-Moser, C | 1 |
| Epstein, M | 3 |
| Kovesdy, CP | 1 |
| Clase, CM | 1 |
| Sood, MM | 1 |
| Pecoits-Filho, R | 1 |
| Qiang, P | 5 |
| Hao, J | 6 |
| Yang, F | 7 |
| Han, Y | 5 |
| Chang, Y | 6 |
| Xian, Y | 4 |
| Xiong, Y | 2 |
| Gao, X | 9 |
| Liang, L | 1 |
| Shimosawa, T | 7 |
| Xu, Q | 6 |
| Ben, Y | 1 |
| Li, H | 2 |
| Chen, G | 1 |
| Ma, X | 1 |
| Wang, X | 7 |
| Araos, P | 4 |
| Amador, CA | 4 |
| Zhai, YS | 2 |
| Li, J | 4 |
| Peng, L | 3 |
| Lu, G | 3 |
| Zheng, H | 2 |
| Ji, J | 2 |
| Zhao, T | 4 |
| Wang, E | 2 |
| Zhang, A | 2 |
| Berkowicz, P | 1 |
| Totoń-Żurańska, J | 1 |
| Kwiatkowski, G | 1 |
| Jasztal, A | 1 |
| Csípő, T | 1 |
| Kus, K | 1 |
| Tyrankiewicz, U | 1 |
| Orzyłowska, A | 1 |
| Wołkow, P | 1 |
| Tóth, A | 1 |
| Chlopicki, S | 1 |
| Nishio, H | 1 |
| Ishii, A | 1 |
| Yamada, H | 1 |
| Mori, KP | 1 |
| Kato, Y | 1 |
| Ohno, S | 1 |
| Handa, T | 1 |
| Sugioka, S | 1 |
| Ishimura, T | 1 |
| Ikushima, A | 1 |
| Inoue, Y | 1 |
| Minamino, N | 1 |
| Mukoyama, M | 2 |
| Yanagita, M | 1 |
| Yokoi, H | 1 |
| Crompton, M | 1 |
| Skinner, LJ | 1 |
| Satchell, SC | 1 |
| Butler, MJ | 1 |
| Chang, J | 2 |
| Fan, L | 1 |
| Liu, Z | 1 |
| Zhang, C | 1 |
| Kmieć, P | 1 |
| Rosenkranz, S | 1 |
| Odenthal, M | 1 |
| Caglayan, E | 1 |
| Shrestha, A | 1 |
| Che, RC | 1 |
| Zhang, AH | 1 |
| Yuan, X | 2 |
| Li, Y | 2 |
| Li, X | 4 |
| Zhang, S | 1 |
| Hao, L | 2 |
| Chen, YH | 3 |
| Rose-John, S | 1 |
| Klapper-Goldstein, H | 2 |
| Murninkas, M | 2 |
| Gillis, R | 2 |
| Mulla, W | 1 |
| Levanon, E | 1 |
| Elyagon, S | 2 |
| Schuster, R | 1 |
| Danan, D | 1 |
| Cohen, H | 1 |
| Etzion, Y | 2 |
| Ibarrola, J | 3 |
| Bonnard, B | 1 |
| Rossignol, P | 7 |
| Leader, CJ | 1 |
| Kelly, DJ | 1 |
| Sammut, IA | 1 |
| Wilkins, GT | 1 |
| Walker, RJ | 1 |
| Zheng, W | 1 |
| Ocorr, K | 1 |
| Tatar, M | 1 |
| Li, S | 3 |
| Cao, W | 1 |
| Wang, B | 2 |
| Zhan, E | 1 |
| Xu, J | 1 |
| Hu, R | 1 |
| Peng, C | 1 |
| Gao, R | 1 |
| Ma, L | 2 |
| Hu, J | 1 |
| Luo, T | 1 |
| Qing, H | 1 |
| Wang, Y | 4 |
| Ge, Q | 1 |
| Wang, Z | 3 |
| Wu, C | 3 |
| Xiao, X | 1 |
| Yang, J | 4 |
| Young, MJ | 5 |
| Li, Q | 1 |
| Yang, S | 1 |
| Hill, MA | 2 |
| Sowers, JR | 3 |
| Verma, A | 1 |
| Pittala, S | 1 |
| Paul, A | 1 |
| Shoshan-Barmatz, V | 1 |
| Wang, CH | 1 |
| Liang, LJ | 1 |
| Wang, XT | 1 |
| Ma, XL | 1 |
| Liu, BB | 1 |
| He, JQ | 1 |
| Xu, QY | 1 |
| Shi, L | 1 |
| Zhao, C | 1 |
| Wang, H | 1 |
| Lei, T | 1 |
| Cao, J | 1 |
| Lu, Z | 1 |
| Donderski, R | 1 |
| Stróżecki, P | 1 |
| Sulikowska, B | 1 |
| Grajewska, M | 1 |
| Miśkowiec, I | 1 |
| Stefańska, A | 1 |
| Siódmiak, J | 1 |
| Odrowąż-Sypniewska, G | 1 |
| Manitius, J | 1 |
| Slavic, S | 1 |
| Ford, K | 1 |
| Modert, M | 1 |
| Becirovic, A | 1 |
| Handschuh, S | 1 |
| Baierl, A | 1 |
| Katica, N | 1 |
| Zeitz, U | 1 |
| Erben, RG | 1 |
| Andrukhova, O | 1 |
| Martínez-Martínez, E | 4 |
| Santamaria, E | 1 |
| Fernández-Irigoyen, J | 1 |
| Zhang, H | 3 |
| Zhang, J | 3 |
| Xie, C | 1 |
| Fan, C | 1 |
| Wu, P | 1 |
| Wei, Q | 1 |
| Tan, W | 1 |
| Xu, L | 1 |
| Wang, L | 1 |
| Xue, Y | 1 |
| Guan, M | 1 |
| Park, EJ | 1 |
| Jung, HJ | 1 |
| Choi, HJ | 1 |
| Cho, JI | 1 |
| Park, HJ | 1 |
| Kwon, TH | 1 |
| Rossi, GP | 1 |
| Seccia, TM | 1 |
| Barton, M | 1 |
| Danser, AHJ | 1 |
| de Leeuw, PW | 1 |
| Dhaun, N | 1 |
| Rizzoni, D | 1 |
| Ruilope, LM | 1 |
| van den Meiracker, AH | 3 |
| Ito, S | 1 |
| Hasebe, N | 1 |
| Webb, DJ | 2 |
| Kraut, JA | 1 |
| Madias, NE | 1 |
| Buonafine, M | 1 |
| Amador, C | 2 |
| Gravez, B | 2 |
| El Moghrabi, S | 2 |
| Wei, LH | 1 |
| Chen, CW | 1 |
| Wan, CH | 1 |
| Wu, KD | 5 |
| Zhang, YD | 1 |
| Ding, XJ | 1 |
| Dai, HY | 1 |
| Peng, WS | 1 |
| Guo, NF | 1 |
| Zhang, Y | 2 |
| Zhou, QL | 1 |
| Chen, XL | 1 |
| Quan, FS | 1 |
| Jeong, KH | 1 |
| Lee, GJ | 1 |
| Zhang, L | 2 |
| Ni, J | 1 |
| Jia, G | 1 |
| Aroor, AR | 1 |
| Sun, WY | 1 |
| Bai, B | 1 |
| Luo, C | 2 |
| Yang, K | 1 |
| Li, D | 1 |
| Wu, D | 1 |
| Félétou, M | 1 |
| Villeneuve, N | 1 |
| Zhou, Y | 1 |
| Xu, A | 1 |
| Vanhoutte, PM | 2 |
| Sogawa, Y | 1 |
| Nagasu, H | 1 |
| Itano, S | 1 |
| Kidokoro, K | 1 |
| Taniguchi, S | 2 |
| Takahashi, M | 2 |
| Kadoya, H | 2 |
| Satoh, M | 2 |
| Sasaki, T | 2 |
| Kashihara, N | 2 |
| Lai, L | 1 |
| Cheng, P | 1 |
| Yan, M | 1 |
| Gu, Y | 4 |
| Xue, J | 1 |
| Huang, Y | 2 |
| Liu, YW | 1 |
| Pan, HZ | 1 |
| Zhang, XL | 1 |
| Xiang, L | 1 |
| Meng, J | 1 |
| Wang, PH | 1 |
| Jing, ZC | 1 |
| Wang, J | 2 |
| Hu, H | 1 |
| Song, J | 1 |
| Yan, F | 1 |
| Qin, J | 1 |
| Guo, X | 1 |
| Cui, C | 1 |
| He, Q | 1 |
| Hou, X | 1 |
| Liu, F | 1 |
| Chen, L | 2 |
| Prado, C | 1 |
| Lozano, M | 1 |
| Figueroa, S | 1 |
| Espinoza, A | 1 |
| Berger, T | 2 |
| Mak, TW | 2 |
| Pacheco, R | 1 |
| Michea, L | 1 |
| Könemann, S | 1 |
| Sartori, LV | 1 |
| Gross, S | 1 |
| Hadlich, S | 1 |
| Kühn, JP | 1 |
| Samal, R | 1 |
| Bahls, M | 1 |
| Felix, SB | 1 |
| Wenzel, K | 1 |
| Yang, Y | 1 |
| Chen, S | 2 |
| Tao, L | 1 |
| Gan, S | 1 |
| Luo, H | 1 |
| Xu, Y | 1 |
| Shen, X | 1 |
| Ocello, A | 1 |
| La Rosa, S | 1 |
| Fiorini, F | 1 |
| Randone, S | 1 |
| Maccarrone, R | 1 |
| Battaglia, G | 1 |
| Granata, A | 1 |
| Preston, IR | 1 |
| Sagliani, KD | 1 |
| Warburton, RR | 1 |
| Hill, NS | 1 |
| Fanburg, BL | 1 |
| Jaffe, IZ | 3 |
| McCurley, A | 2 |
| McGraw, A | 1 |
| Pruthi, D | 2 |
| Azibani, F | 3 |
| Fazal, L | 3 |
| Chatziantoniou, C | 3 |
| Samuel, JL | 3 |
| Delcayre, C | 11 |
| Zhao, Q | 2 |
| Huang, H | 1 |
| Tang, Y | 2 |
| Xiao, J | 2 |
| Dai, Z | 2 |
| Yu, S | 2 |
| Huang, C | 2 |
| Brown, NJ | 5 |
| Tarjus, A | 2 |
| Issa, N | 1 |
| Ortiz, F | 1 |
| Reule, SA | 1 |
| Kukla, A | 1 |
| Kasiske, BL | 1 |
| Mauer, M | 1 |
| Jackson, S | 1 |
| Matas, AJ | 1 |
| Ibrahim, HN | 1 |
| Najafian, B | 1 |
| Dos, L | 1 |
| Pujadas, S | 1 |
| Estruch, M | 1 |
| Mas, A | 1 |
| Ferreira-González, I | 1 |
| Pijuan, A | 1 |
| Serra, R | 1 |
| Ordóñez-Llanos, J | 1 |
| Subirana, M | 1 |
| Pons-Lladó, G | 1 |
| Marsal, JR | 1 |
| García-Dorado, D | 1 |
| Casaldàliga, J | 1 |
| Hattori, T | 1 |
| Murase, T | 1 |
| Sugiura, Y | 1 |
| Nagasawa, K | 1 |
| Takahashi, K | 1 |
| Ohtake, M | 2 |
| Miyachi, M | 1 |
| Murohara, T | 1 |
| Nagata, K | 2 |
| Stanley, WC | 1 |
| Cox, JW | 1 |
| Asemu, G | 1 |
| O'Connell, KA | 1 |
| Dabkowski, ER | 1 |
| Xu, W | 1 |
| Ribeiro, RF | 1 |
| Shekar, KC | 1 |
| Hoag, SW | 1 |
| Rastogi, S | 1 |
| Sabbah, HN | 1 |
| Daneault, C | 1 |
| des Rosiers, C | 2 |
| Shao, L | 1 |
| Ma, A | 1 |
| Guan, G | 1 |
| Tian, G | 1 |
| Tomaschitz, A | 1 |
| Ritz, E | 1 |
| Pieske, B | 1 |
| Rus-Machan, J | 1 |
| Kienreich, K | 1 |
| Verheyen, N | 1 |
| Gaksch, M | 1 |
| Grübler, M | 1 |
| Fahrleitner-Pammer, A | 1 |
| Mrak, P | 1 |
| Toplak, H | 1 |
| Kraigher-Krainer, E | 1 |
| März, W | 1 |
| Pilz, S | 1 |
| Tsai, CF | 1 |
| Yang, SF | 1 |
| Chu, HJ | 1 |
| Ueng, KC | 1 |
| Aronovitz, M | 1 |
| Galayda, C | 1 |
| Karumanchi, SA | 1 |
| Meng, W | 1 |
| Zhao, W | 2 |
| Liu, C | 1 |
| Chen, Y | 2 |
| Liu, H | 1 |
| Sun, Y | 14 |
| Rickard, AJ | 2 |
| Morgan, J | 2 |
| Chrissobolis, S | 1 |
| Miller, AA | 1 |
| Sobey, CG | 1 |
| Doi, T | 1 |
| Doi, S | 1 |
| Nakashima, A | 1 |
| Ueno, T | 1 |
| Yokoyama, Y | 1 |
| Kohno, N | 1 |
| Masaki, T | 2 |
| Al Darazi, F | 1 |
| Marion, TN | 1 |
| Ahokas, RA | 4 |
| Bhattacharya, SK | 3 |
| Gerling, IC | 4 |
| Weber, KT | 22 |
| Zhu, XQ | 1 |
| Hong, HS | 1 |
| Lin, XH | 1 |
| Chen, LL | 1 |
| Li, YH | 1 |
| Meng, Y | 1 |
| He, H | 1 |
| Tzeng, YL | 1 |
| Ho, YL | 3 |
| Hsieh, FJ | 1 |
| Bauersachs, J | 1 |
| Toto, R | 1 |
| Martín-Fernández, B | 5 |
| Valero Muñoz, M | 1 |
| de las Heras, N | 4 |
| Ballesteros, S | 4 |
| Lahera, V | 5 |
| Sun, QL | 1 |
| Li, M | 1 |
| Rui, HL | 1 |
| Chen, YP | 1 |
| Ding, W | 2 |
| Brem, AS | 3 |
| Gong, R | 3 |
| Schwenk, MH | 1 |
| Hirsch, JS | 1 |
| Bomback, AS | 2 |
| Liang, Z | 1 |
| Shi, XM | 1 |
| Liu, LF | 1 |
| Chen, XP | 1 |
| Shan, ZL | 1 |
| Lin, K | 1 |
| Chen, FK | 1 |
| Li, YG | 1 |
| Guo, HY | 1 |
| Wang, YT | 1 |
| Latouche, C | 1 |
| Fay, R | 1 |
| Farman, N | 2 |
| Zannad, F | 3 |
| Adam, O | 1 |
| Zimmer, C | 1 |
| Hanke, N | 1 |
| Hartmann, RW | 1 |
| Klemmer, B | 1 |
| Böhm, M | 2 |
| Laufs, U | 1 |
| Maron, BA | 1 |
| Leopold, JA | 1 |
| Bernardi, S | 1 |
| Toffoli, B | 1 |
| Zennaro, C | 1 |
| Bossi, F | 1 |
| Losurdo, P | 1 |
| Michelli, A | 1 |
| Carretta, R | 1 |
| Mulatero, P | 1 |
| Fallo, F | 1 |
| Veglio, F | 1 |
| Fabris, B | 1 |
| Huby, AC | 1 |
| Antonova, G | 1 |
| Groenendyk, J | 1 |
| Bollag, WB | 1 |
| Filosa, JA | 1 |
| Belin de Chantemèle, EJ | 1 |
| Montes-Cobos, E | 1 |
| Fischer, HJ | 1 |
| Sasse, A | 1 |
| Kügler, S | 1 |
| Didié, M | 1 |
| Toischer, K | 1 |
| Fassnacht, M | 1 |
| Dressel, R | 1 |
| Reichardt, HM | 1 |
| Valero-Muñoz, M | 2 |
| Wilson, RM | 3 |
| Hulsmans, M | 1 |
| Aprahamian, T | 1 |
| Fuster, JJ | 1 |
| Nahrendorf, M | 1 |
| Scherer, PE | 1 |
| Sam, F | 6 |
| Rubio-Navarro, A | 1 |
| Cortegano, I | 1 |
| Alía, M | 1 |
| Cannata-Ortiz, P | 1 |
| Olivares-Álvaro, E | 1 |
| Egido, J | 1 |
| de Andrés, B | 1 |
| Gaspar, ML | 1 |
| Moreno, JA | 1 |
| Gregorini, M | 1 |
| Corradetti, V | 1 |
| Rocca, C | 1 |
| Pattonieri, EF | 1 |
| Valsania, T | 1 |
| Milanesi, S | 1 |
| Serpieri, N | 1 |
| Bedino, G | 1 |
| Esposito, P | 1 |
| Libetta, C | 1 |
| Avanzini, MA | 1 |
| Mantelli, M | 1 |
| Ingo, D | 1 |
| Peressini, S | 1 |
| Albertini, R | 1 |
| Dal Canton, A | 1 |
| Rampino, T | 1 |
| Narita, Y | 1 |
| Ueda, M | 1 |
| Uchimura, K | 1 |
| Kakizoe, Y | 1 |
| Miyasato, Y | 1 |
| Mizumoto, T | 1 |
| Morinaga, J | 1 |
| Hayata, M | 1 |
| Nakagawa, T | 1 |
| Adachi, M | 1 |
| Miyoshi, T | 1 |
| Sakai, Y | 1 |
| Kadowaki, D | 1 |
| Hirata, S | 1 |
| Kitamura, K | 1 |
| Sakamuri, SS | 1 |
| Valente, AJ | 2 |
| Siddesha, JM | 1 |
| Delafontaine, P | 1 |
| Siebenlist, U | 2 |
| Gardner, JD | 1 |
| Bysani, C | 1 |
| Mendoza-Milla, C | 1 |
| Czubryt, MP | 1 |
| Lin, YT | 2 |
| Su, MJ | 1 |
| Chen, MF | 1 |
| de Jong, MA | 1 |
| Mirkovic, K | 1 |
| Mencke, R | 1 |
| Hoenderop, JG | 1 |
| Bindels, RJ | 1 |
| Vervloet, MG | 1 |
| Hillebrands, JL | 1 |
| van den Born, J | 1 |
| Navis, G | 2 |
| de Borst, MH | 2 |
| Liu, Q | 1 |
| Lu, D | 1 |
| Wang, S | 1 |
| Wang, K | 1 |
| Zhang, Q | 1 |
| Fang, P | 1 |
| Li, Z | 1 |
| Geng, J | 1 |
| Shan, Q | 1 |
| Sheng, L | 1 |
| Yang, M | 1 |
| Niu, J | 1 |
| Qiao, Z | 1 |
| Tanino, A | 1 |
| Okura, T | 2 |
| Nagao, T | 2 |
| Kukida, M | 1 |
| Pei, Z | 1 |
| Enomoto, D | 2 |
| Miyoshi, K | 2 |
| Okamura, H | 1 |
| Higaki, J | 2 |
| Mummidi, S | 1 |
| Das, NA | 1 |
| Carpenter, AJ | 1 |
| Kandikattu, H | 1 |
| Krenz, M | 1 |
| Chandrasekar, B | 1 |
| Luo, J | 1 |
| Chen, X | 1 |
| Zuo, Z | 1 |
| Remuzzi, G | 1 |
| Cattaneo, D | 1 |
| Perico, N | 1 |
| Huang, BS | 1 |
| White, RA | 1 |
| Ahmad, M | 1 |
| Tan, J | 1 |
| Jeng, AY | 2 |
| Leenen, FH | 2 |
| Cavallari, LH | 1 |
| Fashingbauer, LA | 1 |
| Camp, JR | 1 |
| King, ST | 1 |
| Geenen, DL | 1 |
| Minnaard-Huiban, M | 2 |
| Hermans, JJ | 2 |
| Essen, Hv | 1 |
| Bitsch, N | 1 |
| Smits, JF | 2 |
| Wu, ZL | 1 |
| Xu, DL | 1 |
| Deng, LH | 1 |
| Wen, YW | 1 |
| Huang, P | 1 |
| Bai, SC | 1 |
| Su, L | 1 |
| Kimura, H | 1 |
| Torii, K | 1 |
| Okada, T | 1 |
| Kamiyama, K | 1 |
| Mikami, D | 1 |
| Takahashi, N | 1 |
| Yoshida, H | 1 |
| Xu, G | 1 |
| Liu, A | 1 |
| Liu, X | 1 |
| Klemmer, PJ | 1 |
| Manger, WM | 1 |
| Simchon, S | 1 |
| Stokes, MB | 1 |
| Reidy, JJ | 1 |
| Kumar, AR | 1 |
| Baer, L | 1 |
| Gallo, G | 1 |
| Haddy, FJ | 1 |
| Kawai, M | 1 |
| Hongo, K | 1 |
| Komukai, K | 1 |
| Morimoto, S | 1 |
| Nagai, M | 1 |
| Seki, S | 1 |
| Taniguchi, I | 2 |
| Mochizuki, S | 2 |
| Yoshimura, M | 1 |
| Klusonová, P | 1 |
| Reháková, L | 1 |
| Borchert, G | 1 |
| Vagnerová, K | 1 |
| Neckár, J | 1 |
| Ergang, P | 1 |
| Miksík, I | 1 |
| Kolár, F | 1 |
| Pácha, J | 1 |
| Jansen, PM | 1 |
| Danser, AH | 1 |
| Imholz, BP | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Fukuda, M | 1 |
| Nako, H | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Ichijo, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| De Silva, DS | 3 |
| Sato, K | 1 |
| Izumiya, Y | 1 |
| Dorrance, AM | 1 |
| Shafiq, MM | 1 |
| Miller, AB | 1 |
| Peters, J | 1 |
| Schlüter, T | 1 |
| Riegel, T | 1 |
| Peters, BS | 1 |
| Beineke, A | 1 |
| Maschke, U | 1 |
| Hosten, N | 1 |
| Mullins, JJ | 1 |
| Rettig, R | 1 |
| Chen, J | 1 |
| You, L | 1 |
| Lin, S | 1 |
| Cetrullo, S | 1 |
| Facchini, A | 1 |
| Stanic, I | 1 |
| Tantini, B | 1 |
| Pignatti, C | 1 |
| Caldarera, CM | 1 |
| Flamigni, F | 1 |
| Kagiyama, S | 2 |
| Matsumura, K | 2 |
| Goto, K | 1 |
| Otsubo, T | 1 |
| Iida, M | 2 |
| Morris, DJ | 2 |
| Ge, Y | 1 |
| Dworkin, L | 1 |
| Tolbert, E | 1 |
| Briet, M | 2 |
| Schiffrin, EL | 7 |
| Fels, J | 1 |
| Oberleithner, H | 1 |
| Kusche-Vihrog, K | 1 |
| Gandhi, MS | 1 |
| Kamalov, G | 1 |
| Shahbaz, AU | 1 |
| Matsui, T | 2 |
| Takeuchi, M | 1 |
| Yamagishi, S | 1 |
| Matsubara, BB | 2 |
| Franco, M | 1 |
| Janicki, JS | 4 |
| Matsubara, LS | 2 |
| Wang, BH | 1 |
| Bertucci, MC | 1 |
| Ma, JY | 1 |
| Adrahtas, A | 1 |
| Cheung, RY | 1 |
| Krum, H | 1 |
| Stehr, CB | 1 |
| Mellado, R | 1 |
| Ocaranza, MP | 1 |
| Carvajal, CA | 1 |
| Mosso, L | 1 |
| Becerra, E | 1 |
| Solis, M | 1 |
| García, L | 1 |
| Lavandero, S | 1 |
| Jalil, J | 1 |
| Fardella, CE | 1 |
| Usher, MG | 1 |
| Duan, SZ | 1 |
| Ivaschenko, CY | 1 |
| Frieler, RA | 1 |
| Berger, S | 1 |
| Schütz, G | 1 |
| Lumeng, CN | 1 |
| Mortensen, RM | 1 |
| Ferreira, DN | 1 |
| Katayama, IA | 1 |
| Oliveira, IB | 1 |
| Rosa, KT | 1 |
| Furukawa, LN | 1 |
| Coelho, MS | 1 |
| Casarini, DE | 1 |
| Heimann, JC | 1 |
| Miana, M | 3 |
| Delgado, C | 1 |
| Song, S | 1 |
| Hintze, T | 1 |
| Cachofeiro, V | 4 |
| Hakki, T | 1 |
| Hübel, K | 1 |
| Waldmann, H | 1 |
| Bernhardt, R | 2 |
| Busseuil, D | 1 |
| Shi, Y | 1 |
| Mecteau, M | 1 |
| Brand, G | 1 |
| Gillis, MA | 1 |
| Thorin, E | 1 |
| Asselin, C | 1 |
| Roméo, P | 1 |
| Leung, TK | 1 |
| Latour, JG | 1 |
| Bouly, M | 1 |
| Rhéaume, E | 1 |
| Tardif, JC | 1 |
| Rabe, S | 1 |
| Schneider, B | 1 |
| Ruhs, S | 1 |
| Grossmann, C | 1 |
| Hauptmann, S | 1 |
| Blessing, M | 1 |
| Neumann, J | 1 |
| Xie, YJ | 2 |
| Wang, SQ | 2 |
| Chen, JS | 2 |
| Bo, XC | 2 |
| Ren, YH | 2 |
| Kurdi, M | 1 |
| Booz, GW | 1 |
| Knier, B | 1 |
| Cordasic, N | 1 |
| Klanke, B | 1 |
| Heusinger-Ribeiro, J | 1 |
| Daniel, C | 1 |
| Veelken, R | 1 |
| Hartner, A | 1 |
| Hilgers, KF | 1 |
| Irita, J | 1 |
| Jotoku, M | 1 |
| Kurata, M | 1 |
| Desilva, VR | 1 |
| Matsui, Y | 2 |
| Uede, T | 2 |
| Denhardt, DT | 1 |
| Rittiling, SR | 1 |
| Reil, JC | 1 |
| Hohl, M | 1 |
| Selejan, S | 1 |
| Lipp, P | 1 |
| Drautz, F | 1 |
| Kazakow, A | 1 |
| Münz, BM | 1 |
| Müller, P | 1 |
| Steendijk, P | 1 |
| Reil, GH | 1 |
| Allessie, MA | 1 |
| Neuberger, HR | 1 |
| Fortuno, MA | 1 |
| Díez, J | 2 |
| Guo, P | 1 |
| Mori, H | 1 |
| Nishiyama, A | 2 |
| He, T | 1 |
| Yang, WQ | 1 |
| Jin, MW | 1 |
| Wu, SY | 1 |
| Yu, YR | 1 |
| Cai, Y | 1 |
| Jia, LX | 1 |
| Xiao, CS | 1 |
| Tang, CS | 1 |
| Qi, YF | 1 |
| Rosin, NL | 1 |
| Sopel, M | 1 |
| Falkenham, A | 1 |
| Myers, TL | 1 |
| Légaré, JF | 1 |
| Vassallo, D | 1 |
| Davel, AP | 1 |
| Rossoni, LV | 1 |
| Mo, Q | 1 |
| Guo, YS | 1 |
| Huang, TT | 1 |
| Ren, L | 1 |
| Benard, L | 1 |
| Schlossarek, S | 1 |
| Merval, R | 1 |
| Tournoux, F | 1 |
| Polidano, E | 1 |
| Launay, JM | 1 |
| Carrier, L | 1 |
| Luther, JM | 1 |
| Luo, P | 1 |
| Cohen, SE | 1 |
| Kim, HS | 2 |
| Fogo, AB | 3 |
| Bienvenu, LA | 1 |
| Tesch, GH | 1 |
| Cranston, GA | 1 |
| Fletcher, EK | 1 |
| Delbridge, LM | 1 |
| Lee, HH | 1 |
| Lee, JK | 1 |
| Liu, YC | 1 |
| Chang, HW | 1 |
| Lin, CY | 1 |
| Chueh, SC | 1 |
| Lin, LC | 1 |
| Lo, MT | 1 |
| Garcia, AG | 1 |
| Heo, J | 1 |
| Murthy, NR | 1 |
| Baid, S | 1 |
| Ouchi, N | 1 |
| Perino, A | 1 |
| Ghigo, A | 1 |
| Hirsch, E | 1 |
| Shah, AM | 1 |
| Lahmer, T | 1 |
| Hermans, R | 1 |
| Schmaderer, C | 1 |
| Stock, K | 1 |
| Lutz, J | 1 |
| Heemann, U | 1 |
| Baumann, M | 1 |
| Matavelli, LC | 1 |
| Siragy, HM | 1 |
| Calvier, L | 1 |
| Reboul, P | 1 |
| de Boer, RA | 2 |
| Poirier, F | 1 |
| Lacolley, P | 2 |
| Martin, FL | 1 |
| Sangaralingham, SJ | 1 |
| Huntley, BK | 1 |
| McKie, PM | 1 |
| Ichiki, T | 1 |
| Chen, HH | 1 |
| Korinek, J | 1 |
| Harders, GE | 1 |
| Burnett, JC | 2 |
| Whaley-Connell, A | 1 |
| Habibi, J | 1 |
| Rehmer, N | 1 |
| Ardhanari, S | 1 |
| Hayden, MR | 1 |
| Pulakat, L | 1 |
| Krueger, C | 1 |
| Ferrario, CM | 1 |
| DeMarco, VG | 1 |
| Lindsay, MM | 1 |
| Maxwell, P | 1 |
| Dunn, FG | 1 |
| Lu, L | 2 |
| Chen, SS | 1 |
| Quinn, MT | 1 |
| Struthers, AD | 5 |
| Funder, JW | 5 |
| Ullian, ME | 1 |
| Gantt, BJ | 1 |
| Ford, AK | 1 |
| Tholanikunnel, BG | 1 |
| Spicer, EK | 1 |
| Fitzgibbon, WR | 1 |
| Swynghedauw, B | 6 |
| Fritsch Neves, M | 1 |
| Blasi, ER | 1 |
| Rocha, R | 2 |
| Rudolph, AE | 2 |
| Blomme, EA | 2 |
| Polly, ML | 1 |
| McMahon, EG | 2 |
| Kambara, A | 1 |
| Holycross, BJ | 1 |
| Wung, P | 1 |
| Schanbacher, B | 1 |
| Ghosh, S | 1 |
| McCune, SA | 1 |
| Bauer, JA | 1 |
| Kwiatkowski, P | 1 |
| Qin, W | 1 |
| Bond, BR | 1 |
| Goellner, JJ | 1 |
| Kiani, MF | 1 |
| Guntaka, RV | 1 |
| Postlethwaite, AE | 1 |
| Warrington, KJ | 1 |
| De, BK | 1 |
| Majumdar, D | 1 |
| Das, D | 1 |
| Biswas, PK | 1 |
| Mandal, SK | 1 |
| Ray, S | 1 |
| Bandopadhyay, K | 1 |
| Das, TK | 1 |
| Dasgupta, S | 1 |
| Guru, S | 1 |
| Ma, LJ | 1 |
| Gaspert, A | 1 |
| Carlesso, G | 1 |
| Barty, MM | 1 |
| Davidson, JM | 1 |
| Sheppard, D | 1 |
| Park, YM | 1 |
| Park, MY | 1 |
| Suh, YL | 1 |
| Park, JB | 2 |
| Bedigian, MP | 1 |
| Robinson, AD | 1 |
| Xie, Z | 1 |
| Ooi, H | 1 |
| Kerstetter, DL | 1 |
| Colucci, WS | 1 |
| Singh, M | 1 |
| Singh, K | 1 |
| González, A | 1 |
| López, B | 1 |
| Tsybouleva, N | 1 |
| Patel, R | 1 |
| Lutucuta, S | 1 |
| Nemoto, S | 1 |
| DeFreitas, G | 1 |
| Entman, M | 1 |
| Carabello, BA | 1 |
| Roberts, R | 1 |
| Marian, AJ | 1 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Hara, Y | 1 |
| Sato, A | 2 |
| Tsuchiya, K | 1 |
| Nishikawa, T | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Endemann, DH | 1 |
| Touyz, RM | 3 |
| Iglarz, M | 2 |
| Savoia, C | 1 |
| Jia, N | 1 |
| Okamoto, H | 1 |
| Kon, S | 1 |
| Onozuka, H | 1 |
| Akino, M | 1 |
| Liu, L | 1 |
| Morimoto, J | 1 |
| Rittling, SR | 1 |
| Denhardt, D | 1 |
| Kitabatake, A | 1 |
| Miyamori, I | 2 |
| Khan, NU | 1 |
| Movahed, A | 1 |
| Saruta, T | 1 |
| Viel, EC | 1 |
| Amiri, F | 2 |
| De Mello, WC | 1 |
| Huizenga, AT | 1 |
| Boomsma, F | 1 |
| Gröholm, T | 1 |
| Finckenberg, P | 2 |
| Palojoki, E | 2 |
| Saraste, A | 1 |
| Bäcklund, T | 2 |
| Eriksson, A | 2 |
| Laine, M | 2 |
| Mervaala, E | 2 |
| Tikkanen, I | 2 |
| Opie, LH | 1 |
| Saito, K | 1 |
| Ishizaka, N | 1 |
| Aizawa, T | 1 |
| Sata, M | 1 |
| Iso-o, N | 1 |
| Noiri, E | 1 |
| Mori, I | 1 |
| Ohno, M | 1 |
| Nagai, R | 1 |
| Yamada, T | 1 |
| Kuno, A | 1 |
| Ogawa, K | 1 |
| Tang, M | 1 |
| Masuda, K | 1 |
| Nakamura, S | 2 |
| Ando, T | 1 |
| Okamoto, T | 1 |
| Ohara, H | 1 |
| Nomura, T | 1 |
| Joh, T | 1 |
| Shirai, T | 1 |
| Itoh, M | 1 |
| Bos, R | 1 |
| Mougenot, N | 2 |
| Findji, L | 1 |
| Médiani, O | 1 |
| Lechat, P | 2 |
| Yamamoto, T | 3 |
| Yano, M | 1 |
| Caló, LA | 1 |
| Pagnin, E | 1 |
| Davis, PA | 1 |
| Armanini, D | 1 |
| Kurabayashi, M | 1 |
| Fujii, M | 2 |
| Wada, A | 2 |
| Ohnishi, M | 2 |
| Tsutamoto, T | 2 |
| Matsumoto, T | 2 |
| Takayama, T | 1 |
| Dohke, T | 1 |
| Isono, T | 1 |
| Eguchi, Y | 1 |
| Horie, M | 1 |
| Fiebeler, A | 1 |
| Nussberger, J | 1 |
| Shagdarsuren, E | 1 |
| Rong, S | 1 |
| Hilfenhaus, G | 1 |
| Al-Saadi, N | 1 |
| Dechend, R | 1 |
| Wellner, M | 1 |
| Meiners, S | 1 |
| Maser-Gluth, C | 1 |
| Webb, RL | 1 |
| Luft, FC | 1 |
| Muller, DN | 1 |
| Venco, A | 1 |
| Grandi, AM | 1 |
| Cittadini, A | 1 |
| Serpico, R | 1 |
| Monti, MG | 1 |
| Saccà, L | 1 |
| Lal, A | 1 |
| Veinot, JP | 1 |
| Ganten, D | 1 |
| Grönholm, T | 1 |
| Cheng, ZJ | 1 |
| Vuolteenaho, O | 1 |
| Francois, H | 1 |
| Athirakul, K | 1 |
| Howell, D | 1 |
| Dash, R | 1 |
| Mao, L | 1 |
| Rockman, HA | 1 |
| Fitzgerald, GA | 1 |
| Koller, BH | 1 |
| Coffman, TM | 1 |
| Cataliotti, A | 1 |
| Neves, MF | 1 |
| Virdis, A | 1 |
| Diep, QN | 1 |
| Abe, Y | 2 |
| Rodríguez-Ayala, E | 1 |
| Avila-Díaz, M | 1 |
| Foyo-Niembro, E | 1 |
| Amato, D | 1 |
| Ramirez-San-Juan, E | 1 |
| Paniagua, R | 1 |
| Tsukamoto, O | 1 |
| Minamino, T | 1 |
| Sanada, S | 1 |
| Okada, K | 1 |
| Hirata, A | 1 |
| Fujita, M | 1 |
| Shintani, Y | 1 |
| Yulin, L | 1 |
| Asano, Y | 1 |
| Takashima, S | 1 |
| Yamasaki, S | 1 |
| Tomoike, H | 1 |
| Hori, M | 1 |
| Kitakaze, M | 1 |
| Kawai, Y | 1 |
| Fan, CY | 1 |
| van Timmeren, MM | 1 |
| Vaidya, VS | 1 |
| van Dalen, MB | 1 |
| Kramer, AB | 1 |
| Schuurs, TA | 1 |
| Bonventre, JV | 1 |
| van Goor, H | 1 |
| Gullulu, M | 1 |
| Akdag, I | 1 |
| Kahvecioglu, S | 1 |
| Filiz, G | 1 |
| Savci, V | 1 |
| Urabe, A | 1 |
| Izumi, T | 1 |
| Duhaney, TA | 2 |
| Cui, L | 2 |
| Rude, MK | 1 |
| Lebrasseur, NK | 2 |
| Ngoy, S | 1 |
| Siwik, DA | 1 |
| Liao, R | 1 |
| Hwang, HS | 1 |
| Cirrincione, G | 1 |
| Thomas, DP | 1 |
| McCormick, RJ | 1 |
| Boluyt, MO | 1 |
| Nishioka, T | 1 |
| Suzuki, M | 1 |
| Onishi, K | 1 |
| Takakura, N | 1 |
| Inada, H | 1 |
| Yoshida, T | 1 |
| Hiroe, M | 1 |
| Imanaka-Yoshida, K | 1 |
| Ip, PC | 1 |
| Joseph, L | 1 |
| Thomas, M | 1 |
| Vidal, A | 1 |
| Emmen, JM | 1 |
| Roumen, L | 1 |
| Beugels, IP | 1 |
| Cohuet, GM | 1 |
| van Essen, H | 1 |
| Ruijters, E | 1 |
| Pieterse, K | 1 |
| Hilbers, PA | 1 |
| Ottenheijm, HC | 1 |
| Plate, R | 1 |
| de Gooyer, ME | 1 |
| Takeda, Y | 2 |
| Zhu, A | 1 |
| Yoneda, T | 2 |
| Usukura, M | 2 |
| Takata, H | 1 |
| Yamagishi, M | 1 |
| Fukuhara, M | 1 |
| Sakagami, K | 1 |
| Fujii, K | 1 |
| Terada, Y | 1 |
| Kuwana, H | 1 |
| Kobayashi, T | 1 |
| Okado, T | 1 |
| Suzuki, N | 1 |
| Yoshimoto, T | 1 |
| Hirata, Y | 1 |
| Sasaki, S | 1 |
| Sontia, B | 1 |
| Montezano, AC | 1 |
| Paravicini, T | 1 |
| Tabet, F | 1 |
| Zöllner, S | 1 |
| Hwang, KH | 1 |
| Wilzewski, B | 1 |
| Carapito, C | 1 |
| Leize-Wagner, E | 1 |
| Van Dorsselaer, A | 1 |
| Huang, W | 1 |
| Xu, C | 1 |
| Kahng, KW | 1 |
| Noble, NA | 1 |
| Border, WA | 1 |
| Chun, TY | 1 |
| Chander, PN | 1 |
| Kim, JW | 1 |
| Pratt, JH | 1 |
| Stier, CT | 1 |
| Young, M | 1 |
| Head, G | 1 |
| Funder, J | 2 |
| Robert, V | 6 |
| Silvestre, JS | 5 |
| Charlemagne, D | 2 |
| Sabri, A | 2 |
| Trouvé, P | 2 |
| Wassef, M | 2 |
| Ratajska, A | 2 |
| Fullerton, MJ | 1 |
| Besse, S | 1 |
| Van Thiem, N | 1 |
| Zhou, G | 1 |
| Campbell, SE | 2 |
| Brilla, CG | 6 |
| Cleutjens, JP | 1 |
| Ramires, FJ | 2 |
| McEwan, PE | 1 |
| Gray, GA | 1 |
| Sherry, L | 1 |
| Kenyon, CJ | 1 |
| Ramirez-Gil, JF | 1 |
| Heymes, C | 2 |
| Oubénaïssa, A | 2 |
| Aupetit-Faisant, B | 1 |
| Carayon, A | 1 |
| Slight, SH | 1 |
| Joseph, J | 1 |
| Ganjam, VK | 1 |
| Garnier, A | 1 |
| Cailmail, S | 1 |
| Tatara, E | 1 |
| Farina, NK | 1 |
| Johnston, CI | 1 |
| Burrell, LM | 1 |
| Lijnen, P | 1 |
| Petrov, V | 1 |
| Nakamura, I | 1 |
| Donnert, E | 1 |
| Freeman, M | 1 |
| Vaughan, DE | 1 |
| Pasquale, PD | 1 |
| Stefano, GD | 1 |
| Paterna, S | 1 |
| Safar, ME | 1 |
| Lucet, B | 1 |
| Ledudal, K | 1 |
| Labat, C | 1 |
| Benetos, A | 1 |
| Peng, H | 1 |
| Carretero, OA | 1 |
| Raij, L | 1 |
| Kapke, A | 1 |
| Rhaleb, NE | 1 |
| Rerolle, JP | 1 |
| Vigneau, C | 1 |
| Hertig, A | 1 |
| Berrou, J | 1 |
| Rondeau, E | 1 |
| Hayashi, M | 1 |
| Maeda, K | 1 |
| Mabuchi, N | 1 |
| Tsutsui, T | 1 |
| Horie, H | 1 |
| Kinoshita, M | 1 |
| Quattropani, C | 1 |
| Odermatt, A | 1 |
| Frey, BM | 1 |
| Frey, FJ | 1 |
| Molteni, A | 1 |
| Moulder, JE | 1 |
| Cohen, EP | 1 |
| Fish, BL | 1 |
| Taylor, JM | 1 |
| Veno, PA | 1 |
| Wolfe, LF | 1 |
| Ward, WF | 1 |
| Demura, M | 1 |
| Mabuchi, H | 1 |
| Pick, R | 1 |
| Tan, LB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients[NCT00067990] | Phase 4 | 153 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Aldosterone Antagonists in Systemic Right Ventricle: a Randomized Clinical Trial.[NCT00703352] | Phase 4 | 26 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial[NCT03049540] | Phase 3 | 100 participants (Actual) | Interventional | 2017-10-25 | Completed | ||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA[NCT01681823] | Phase 2 | 60 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [NCT00005757] | 293 participants (Actual) | Observational | 1997-09-30 | Completed | |||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Doubling of the interstitial or any defined ESRD (including IF/TA) (NCT00067990)
Timeframe: Baseline to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 6 |
| Placebo | 12 |
Number of subjects who had doubling of the interstitial or any end stage renal disease (ESRD) not attributed to interstitial fibrosis and tubular atrophy (IF/TA) (NCT00067990)
Timeframe: Baseline and 5 Years Post Transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 7 |
| Placebo | 15 |
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
70 reviews available for aldosterone and Fibrosis
| Article | Year |
|---|---|
Mineralocorticoid receptors in non-alcoholic fatty liver disease.
Topics: Aldosterone; Fibrosis; Homeostasis; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Rece | 2022 |
Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight.
Topics: Aldosterone; Fibrosis; Humans; Hyperaldosteronism; Hypertension; Kidney | 2022 |
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Fibrosis; Humans; Hyperkalemia; Inflammation; Mineralocortic | 2022 |
Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.
Topics: Adrenal Gland Diseases; Aldosterone; Biomarkers; Fibrosis; Humans; Hypertension; Immunologic Factors | 2022 |
Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.
Topics: Adrenal Gland Diseases; Aldosterone; Biomarkers; Fibrosis; Humans; Hypertension; Immunologic Factors | 2022 |
Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.
Topics: Adrenal Gland Diseases; Aldosterone; Biomarkers; Fibrosis; Humans; Hypertension; Immunologic Factors | 2022 |
Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.
Topics: Adrenal Gland Diseases; Aldosterone; Biomarkers; Fibrosis; Humans; Hypertension; Immunologic Factors | 2022 |
Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.
Topics: Adrenal Gland Diseases; Aldosterone; Biomarkers; Fibrosis; Humans; Hypertension; Immunologic Factors | 2022 |
Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.
Topics: Adrenal Gland Diseases; Aldosterone; Biomarkers; Fibrosis; Humans; Hypertension; Immunologic Factors | 2022 |
Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.
Topics: Adrenal Gland Diseases; Aldosterone; Biomarkers; Fibrosis; Humans; Hypertension; Immunologic Factors | 2022 |
Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.
Topics: Adrenal Gland Diseases; Aldosterone; Biomarkers; Fibrosis; Humans; Hypertension; Immunologic Factors | 2022 |
Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.
Topics: Adrenal Gland Diseases; Aldosterone; Biomarkers; Fibrosis; Humans; Hypertension; Immunologic Factors | 2022 |
Aldosterone: Essential for Life but Damaging to the Vascular Endothelium.
Topics: Aldosterone; Endothelial Cells; Endothelium, Vascular; Fibrosis; Humans; Mineralocorticoid Receptor | 2023 |
Role of Aldosterone in Renal Fibrosis.
Topics: Aldosterone; Fibrosis; Humans; Kidney; Mineralocorticoid Receptor Antagonists | 2019 |
Role of the vascular endothelial sodium channel activation in the genesis of pathologically increased cardiovascular stiffness.
Topics: Aldosterone; Coronary Circulation; Coronary Vessels; Endothelial Cells; Epithelial Sodium Channels; | 2022 |
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: General mechanisms: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and The Japanese Society
Topics: Aldosterone; Animals; Arterial Pressure; Consensus; Endothelin-1; Endothelium, Vascular; Fibrosis; G | 2018 |
Retarding progression of chronic kidney disease: use of modalities that counter acid retention.
Topics: Acid-Base Imbalance; Aldosterone; Angiotensin II; Animals; Buffers; Citrates; Dietary Proteins; Dise | 2018 |
Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness.
Topics: Aldosterone; Cardiovascular Diseases; Cardiovascular System; Fibrosis; Humans; Hypertension; Models, | 2018 |
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nep | 2019 |
Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease.
Topics: Aging; Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiovascular Disease | 2013 |
Aldosterone mediates cardiac fibrosis in the setting of hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Cytochrome P-450 CYP11B2; Fibrosis; Heart Diseases; Humans; Hy | 2013 |
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.
Topics: Aldosterone; Animals; Aromatase Inhibitors; Cardiovascular System; Cytochrome P-450 CYP11B2; Endothe | 2013 |
Mineralocorticoid receptor and cardiac arrhythmia.
Topics: Aldosterone; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Death, Sudden, Cardiac; Fibrosis; H | 2013 |
Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Topics: Adrenalectomy; Aldosterone; Animals; Bone Density; Bone Diseases; Calcium; Cardiovascular Diseases; | 2014 |
Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Animals; Blood Pressure; Clinical Trials as Topi | 2015 |
Relevance of SGK1 in structural, functional and molecular alterations produced by aldosterone in heart.
Topics: Aldosterone; Animals; Cardiomegaly; Connective Tissue Growth Factor; Endothelium, Vascular; Fibrosis | 2014 |
Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.
Topics: Aldosterone; Animals; Drug Design; Fibrosis; Humans; Kidney Diseases; Kidney Glomerulus; Mineralocor | 2015 |
Aldosterone blockade in CKD: emphasis on pharmacology.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biological | 2015 |
Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension.
Topics: Aldosterone; Fibrosis; Heart Ventricles; Humans; Hypertension, Pulmonary; Neurotransmitter Agents; P | 2015 |
Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology.
Topics: Aging; Aldosterone; Cardiovascular Diseases; Eye Diseases; Fibrosis; Humans; Inflammation; Ion Chann | 2016 |
Mineralocorticoid antagonism and cardiac hypertrophy.
Topics: Aldosterone; Antihypertensive Agents; Cardiomegaly; Fibrosis; Humans; Hyperaldosteronism; Hypertensi | 2008 |
Extracellular volume and aldosterone interaction in chronic kidney disease.
Topics: Aldosterone; Cardiovascular Diseases; Chronic Disease; Extracellular Fluid; Fibrosis; Humans; Inflam | 2009 |
Aldosterone-receptor antagonism in hypertension.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; D | 2009 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; | 2009 |
Aldosterone: effects on the kidney and cardiovascular system.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2010 |
Ménage à trois: aldosterone, sodium and nitric oxide in vascular endothelium.
Topics: Aldosterone; Animals; Blood Pressure; Cell Membrane; Cell Size; Endothelium, Vascular; Fibrosis; Hum | 2010 |
Cellular and molecular pathways to myocardial necrosis and replacement fibrosis.
Topics: Aldosterone; Animals; Disease Models, Animal; Fibrosis; Heart Failure; Humans; Hypercalciuria; Hyper | 2011 |
This is not Dr. Conn's aldosterone anymore.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2011 |
Aldosterone-induced fibrosis in the kidney: questions and controversies.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Antihypertensive Agents; Blood Pressure; Child, | 2011 |
NADPH oxidases in heart failure: poachers or gamekeepers?
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Arrhythmias, Cardiac; Enzyme Activation; Fibroblast | 2013 |
Vascular actions of aldosterone.
Topics: Adipocytes; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Vessels; Cardiovasc | 2013 |
Aldosterone: cardiovascular assault.
Topics: Aldosterone; Autonomic Nervous System Diseases; Cardiomegaly; Endothelium, Vascular; Fibrinolysis; F | 2002 |
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibr | 2002 |
Molecular mechanisms of myocardial remodeling. The role of aldosterone.
Topics: Aldosterone; Animals; Cardiomyopathies; Female; Fibrosis; Heart Failure; Humans; Mice; Mice, Transge | 2002 |
Aldosterone: a risk factor for vascular disease.
Topics: Aldosterone; Animals; Arteries; Fibrosis; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoi | 2003 |
Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets.
Topics: Aldosterone; Animals; Biomarkers; Coronary Circulation; Fibrosis; Heart Failure; Humans; Hyperaldost | 2003 |
Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Collagen; Fibrosis; | 2004 |
Aldosterone-induced vasculopathy.
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Fibrosis; Heart Arrest; Heart Failure; Humans; | 2004 |
[Involvement of Aldosterone and mineralocorticoid receptor in pathogenesis of cardiovascular diseases].
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Angiotensin II; Cardiovascular Diseases; F | 2004 |
The role of aldosterone and aldosterone-receptor antagonists in heart failure.
Topics: Aldosterone; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; My | 2004 |
Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Humans; Mice; Mice, Transgenic; Re | 2004 |
Heart failure: how important is cellular sequestration? The role of the renin-angiotensin-aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac | 2004 |
The clinical implications of aldosterone escape in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Endothelium, Vascular | 2004 |
[Profibrotic effects of aldosterone].
Topics: Aldosterone; Animals; Fibrosis; Heart Diseases; Humans; Mineralocorticoid Receptor Antagonists; Myoc | 2004 |
Aldosterone blockade in cardiovascular disease.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiology; Cardiovascular Diseases; | 2004 |
[Aldosterone antagonist therapy for chronic heart failure].
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Diuretics; Eplerenone; Fibrosis; Heart Failure | 2005 |
Aldosterone and end-organ damage.
Topics: Aldosterone; Cardiovascular Diseases; Fibrosis; Humans; Kidney Diseases; Mineralocorticoid Receptor | 2005 |
[PPARs and fibrosis].
Topics: Adipocytes; Aldosterone; Animals; Connective Tissue Growth Factor; Fibrosis; Immediate-Early Protein | 2005 |
Pathophysiology of heart failure following myocardial infarction.
Topics: Aldosterone; Angiotensins; Fibrosis; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardia | 2005 |
[Aldosterone blockade in essential hypertension].
Topics: Aldosterone; Fibrosis; Humans; Hypertension; Inflammation; Mineralocorticoid Receptor Antagonists | 2005 |
[The role of aldosterone in the development of postinfarction fibrosis].
Topics: Aldosterone; Animals; Fibrosis; Forecasting; Humans; Myocardium | 2005 |
Natriuretic peptides: novel therapeutic targets in heart failure.
Topics: Aldosterone; Animals; Fibrosis; Heart; Heart Failure; Humans; Natriuresis; Natriuretic Peptides | 2005 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade.
Topics: Aldosterone; Animals; Cell Proliferation; Cell Shape; Cells, Cultured; Collagen; Eplerenone; Fibrobl | 2006 |
[Cardiovascular action of aldosterone].
Topics: Aldosterone; Animals; Cardiovascular Diseases; Endothelium, Vascular; Epithelial Sodium Channels; Ep | 2006 |
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
Topics: Aldosterone; Algorithms; Disease Progression; Disease Susceptibility; Drug Labeling; Eplerenone; Fib | 2006 |
Mineralocorticoids, salt, hypertension: effects on the heart.
Topics: Aldosterone; Animals; Cardiomegaly; Fibrosis; Heart; Humans; Hypertension; Hypokalemia; Mineralocort | 1996 |
Structural remodeling of the infarcted rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Collagen; Fibrosis; Humans; Metalloendopeptidases; Myocardial | 1996 |
Extra-adrenal mineralocorticoids and cardiovascular tissue.
Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Animals; Cardiovascular System; Cells, Cultured; Collage | 1999 |
Aldosterone and the heart: towards a physiological function?
Topics: Adrenal Cortex; Aldosterone; Angiotensin II; Animals; Cytochrome P-450 CYP11B2; Fibrosis; Gene Expre | 1999 |
Cardiac aldosterone production and ventricular remodeling.
Topics: Aldosterone; Animals; Fibrosis; Humans; Myocardial Infarction; Myocardium; Ventricular Remodeling | 2000 |
Induction of cardiac fibrosis by aldosterone.
Topics: Aldosterone; Animals; Collagen; Fibroblasts; Fibrosis; Heart; Heart Diseases; Humans; Mineralocortic | 2000 |
Aldosterone and myocardial fibrosis in heart failure.
Topics: Adult; Aldosterone; Animals; Cardiomyopathies; Dose-Response Relationship, Drug; Fibrosis; Heart Fai | 2000 |
Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Blood Vessels; Cardiovasc | 2000 |
[Plasminogen activator inhibitor type 1: physiology and role in renal physiopathology].
Topics: Aldosterone; Fibrinolysis; Fibrosis; Humans; Kidney; Kidney Diseases; Kidney Transplantation; Plasmi | 2001 |
Aldosterone as a determinant of cardiovascular and renal dysfunction.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Endothelium, Vascular; Fibrosis; Huma | 2001 |
Mineralocorticoids and cardiac fibrosis: the decade in review.
Topics: Aldosterone; Animals; Clinical Trials as Topic; Epithelium; Fibrosis; Humans; Mineralocorticoids; My | 2001 |
Factors associated with reactive and reparative fibrosis of the myocardium.
Topics: Aldosterone; Animals; Cardiomyopathies; Fibroblasts; Fibrosis; Humans; Myocardium; Necrosis; Wound H | 1992 |
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.
Topics: Aldosterone; Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Models, Cardiovascular; Myocardi | 1991 |
3 trials available for aldosterone and Fibrosis
| Article | Year |
|---|---|
The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure.
Topics: Adult; Albuminuria; Aldosterone; Allografts; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Bi | 2014 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Aldosterone; Cardiomyopathies; Echocardiography; Fe | 2012 |
207 other studies available for aldosterone and Fibrosis
| Article | Year |
|---|---|
AIM2 inflammasome contributes to aldosterone-induced renal injury via endoplasmic reticulum stress.
Topics: Acute Kidney Injury; Aldosterone; Animals; DNA-Binding Proteins; Endoplasmic Reticulum Stress; Fibro | 2022 |
Myeloid mineralocorticoid receptors contribute to skeletal muscle repair in muscular dystrophy and acute muscle injury.
Topics: Aldosterone; Animals; Barium Compounds; Chlorides; Cytokines; Diaphragm; Disease Models, Animal; Fem | 2022 |
Serum galectin-3 and aldosterone: potential biomarkers of cardiac complications in patients with COVID-19.
Topics: Actins; Aldosterone; Biomarkers; COVID-19; Fibrosis; Galectin 3; Humans; SARS-CoV-2; Troponin I | 2022 |
Sex-Related Signaling of Aldosterone/Mineralocorticoid Receptor Pathway in Calcific Aortic Stenosis.
Topics: Aldosterone; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cells, Cultured; Female; Fibrosis; Hum | 2022 |
Autonomous cortisol secretion is associated with worse arterial stiffness and vascular fibrosis in primary aldosteronism: a cross-sectional study with follow-up data.
Topics: Aldosterone; Ankle Brachial Index; Cross-Sectional Studies; Fibrosis; Follow-Up Studies; Humans; Hyd | 2022 |
Increased glucocorticoid metabolism in diabetic kidney disease.
Topics: Aldosterone; Diabetes Mellitus; Diabetic Nephropathies; Endothelial Cells; Female; Fibrosis; Glucoco | 2022 |
Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone.
Topics: Aldosterone; Animals; Eplerenone; Fibrosis; Macrophages; Mice; Myofibroblasts; Pyrroles; Rats; Recep | 2022 |
Eplerenone Prevents Cardiac Fibrosis by Inhibiting Angiogenesis in Unilateral Urinary Obstruction Rats.
Topics: Actins; Aldosterone; Animals; Collagen; Eosine Yellowish-(YS); Eplerenone; Fibrosis; Glucocorticoids | 2022 |
Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway.
Topics: Aldosterone; Animals; Cardio-Renal Syndrome; Eplerenone; Fibrosis; Heart Diseases; Macrophages; Myof | 2022 |
Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway.
Topics: Aldosterone; Animals; Cardio-Renal Syndrome; Eplerenone; Fibrosis; Heart Diseases; Macrophages; Myof | 2022 |
Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway.
Topics: Aldosterone; Animals; Cardio-Renal Syndrome; Eplerenone; Fibrosis; Heart Diseases; Macrophages; Myof | 2022 |
Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway.
Topics: Aldosterone; Animals; Cardio-Renal Syndrome; Eplerenone; Fibrosis; Heart Diseases; Macrophages; Myof | 2022 |
Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction.
Topics: Aldosterone; Animals; Arginine Vasopressin; Collagen Type I; Endothelial Cells; Fibrosis; Heart; Myo | 2022 |
Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction.
Topics: Aldosterone; Animals; Arginine Vasopressin; Collagen Type I; Endothelial Cells; Fibrosis; Heart; Myo | 2022 |
Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction.
Topics: Aldosterone; Animals; Arginine Vasopressin; Collagen Type I; Endothelial Cells; Fibrosis; Heart; Myo | 2022 |
Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction.
Topics: Aldosterone; Animals; Arginine Vasopressin; Collagen Type I; Endothelial Cells; Fibrosis; Heart; Myo | 2022 |
Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway.
Topics: 3' Untranslated Regions; Aldosterone; Animals; Connective Tissue Growth Factor; Exosomes; Fibrosis; | 2023 |
Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway.
Topics: 3' Untranslated Regions; Aldosterone; Animals; Connective Tissue Growth Factor; Exosomes; Fibrosis; | 2023 |
Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway.
Topics: 3' Untranslated Regions; Aldosterone; Animals; Connective Tissue Growth Factor; Exosomes; Fibrosis; | 2023 |
Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway.
Topics: 3' Untranslated Regions; Aldosterone; Animals; Connective Tissue Growth Factor; Exosomes; Fibrosis; | 2023 |
Accelerated ageing and coronary microvascular dysfunction in chronic heart failure in Tgαq*44 mice.
Topics: Aging; Aldosterone; Angiotensins; Animals; Chronic Disease; Fibrosis; Heart Failure; Mice; Mice, Inb | 2023 |
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Topics: Aldosterone; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosi | 2023 |
Esaxerenone Inhibits Renal Angiogenesis and Endothelial-Mesenchymal Transition via the VEGFA and TGF-β1 Pathways in Aldosterone-Infused Mice.
Topics: Aldosterone; Animals; Endothelial Cells; Epithelial-Mesenchymal Transition; Fibrosis; Inflammation; | 2023 |
Differential Role of Aldosterone and Transforming Growth Factor Beta-1 in Cardiac Remodeling.
Topics: Aldosterone; Animals; Cardiomegaly; Eplerenone; Fibrosis; Male; Mice; Mice, Transgenic; Myocytes, Ca | 2023 |
Aldosterone promotes renal interstitial fibrosis via the AIF‑1/AKT/mTOR signaling pathway.
Topics: Aldosterone; Animals; Calcium-Binding Proteins; Collagen; Computational Biology; Fibrosis; Humans; M | 2019 |
Interleukin-6 plays a critical role in aldosterone-induced macrophage recruitment and infiltration in the myocardium.
Topics: Aldosterone; Animals; Cell Line, Tumor; Fibrosis; Humans; Interleukin-6; Macrophages; Male; Mice; Mi | 2020 |
An implantable system for long-term assessment of atrial fibrillation substrate in unanesthetized rats exposed to underlying pathological conditions.
Topics: Aldosterone; Animals; Atrial Fibrillation; Disease Models, Animal; Electrodes, Implanted; Fibrosis; | 2020 |
A New Role for the Aldosterone/Mineralocorticoid Receptor Pathway in the Development of Mitral Valve Prolapse.
Topics: Aged; Aldosterone; Animals; Case-Control Studies; Cell Differentiation; Cells, Cultured; Cytokines; | 2020 |
Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat.
Topics: Aldosterone; Animals; Blood Pressure; Disease Models, Animal; Fibrosis; Hypertension; Kidney Disease | 2020 |
Extracellular matrix induced by steroids and aging through a G-protein-coupled receptor in a
Topics: Age Factors; Aldosterone; Animals; Animals, Genetically Modified; Collagen Type IV; Disease Models, | 2020 |
TRIF/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling.
Topics: Adaptor Proteins, Vesicular Transport; Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Fibrosi | 2020 |
miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes.
Topics: Aldosterone; Animals; Diabetes Mellitus; Diabetic Nephropathies; Epithelial Cells; Extracellular Ves | 2020 |
VDAC1 in the diseased myocardium and the effect of VDAC1-interacting compound on atrial fibrosis induced by hyperaldosteronism.
Topics: Aldosterone; Animals; Apoptosis; Calcium Signaling; Cytochromes c; Disease Models, Animal; Fibrosis; | 2020 |
The Inhibitory Effect of Eplerenone on Cell Proliferation in the Contralateral Kidneys of Rats with Unilateral Ureteral Obstruction.
Topics: Actins; Aldosterone; Animals; Cell Proliferation; Collagen; Eplerenone; Fibrosis; Immediate-Early Pr | 2017 |
Dimethylarginine Dimethylaminohydrolase 1 Deficiency Induces the Epithelial to Mesenchymal Transition in Renal Proximal Tubular Epithelial Cells and Exacerbates Kidney Damage in Aged and Diabetic Mice.
Topics: Aging; Aldosterone; Amidohydrolases; Animals; Arginine; Cell Line; Creatinine; Diabetes Mellitus, Ex | 2017 |
Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cardiovascular Diseases; Ch | 2017 |
Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.
Topics: Aldosterone; Animals; Biomarkers; Blood Pressure; Cardiomegaly; Disease Models, Animal; Disease Susc | 2017 |
Differential Proteomics Identifies Reticulocalbin-3 as a Novel Negative Mediator of Collagen Production in Human Cardiac Fibroblasts.
Topics: Aldosterone; Blood Proteins; Calcium-Binding Proteins; Cell Line; Collagen; CRISPR-Cas Systems; Cyto | 2017 |
Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma.
Topics: 3T3-L1 Cells; Adenoma; Adipocytes, Brown; Adipogenesis; Adipokines; Adrenalectomy; Aldosterone; Anim | 2018 |
miR-34c-5p and CaMKII are involved in aldosterone-induced fibrosis in kidney collecting duct cells.
Topics: Actins; Aldosterone; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Line; Disease | 2018 |
Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation.
Topics: Aldosterone; Animals; Atrial Remodeling; Cell Proliferation; Cells, Cultured; Fibroblasts; Fibrosis; | 2018 |
IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis.
Topics: Adult; Aldosterone; Animals; Cardiomegaly; Case-Control Studies; Cells, Cultured; Collagen; Cytokine | 2018 |
SB-216763, a GSK-3β inhibitor, protects against aldosterone-induced cardiac, and renal injury by activating autophagy.
Topics: Aldosterone; Animals; Autophagy; Cytokines; Fibrosis; Glycogen Synthase Kinase 3 beta; Heart Disease | 2018 |
Ultrastructural and mechanical changes in tubular epithelial cells by angiotensin II and aldosterone as observed with atomic force microscopy.
Topics: Aldosterone; Angiotensin II; Animals; Cell Line; Epithelial Cells; Fibrosis; Kidney Tubules, Proxima | 2018 |
Upregulation of allograft inflammatory factor‑1 expression and secretion by macrophages stimulated with aldosterone promotes renal fibroblasts to a profibrotic phenotype.
Topics: Aldosterone; Animals; Calcium-Binding Proteins; Cell Line; Fibroblasts; Fibrosis; Kidney; Kidney Dis | 2018 |
Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury.
Topics: Acute Kidney Injury; Adipose Tissue; Aldosterone; Alleles; Animals; Biomarkers; Disease Models, Anim | 2018 |
The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice.
Topics: Aldosterone; Animals; Antihypertensive Agents; Disease Models, Animal; Endothelium; Fibrosis; Humans | 2018 |
Aldosterone induces renal fibrosis by promoting HDAC1 expression, deacetylating H3K9 and inhibiting klotho transcription.
Topics: Acetylation; Adult; Aged; Aged, 80 and over; Aldosterone; Animals; Down-Regulation; Female; Fibronec | 2019 |
Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension.
Topics: Adolescent; Aldosterone; Animals; Child, Preschool; Cytokines; Disease Progression; Female; Fibrosis | 2019 |
Aldosterone induced up-expression of ICAM-1 and ET-1 in pancreatic islet endothelium may associate with progression of T2D.
Topics: Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progressio | 2019 |
Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation.
Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; CD11 Antigens; Coculture Techniques; Dend | 2019 |
Cardioprotective effect of the secretome of Sca-1+ and Sca-1- cells in heart failure: not equal, but equally important?
Topics: Aldosterone; Animals; Ataxin-1; Cells, Cultured; Disease Models, Animal; Female; Fibrosis; Galectin | 2020 |
Inhibitory Effects of Oxymatrine on Transdifferentiation of Neonatal Rat Cardiac Fibroblasts to Myofibroblasts Induced by Aldosterone via Keap1/Nrf2 Signaling Pathways In Vitro.
Topics: Aldosterone; Alkaloids; Animals; Animals, Newborn; Cell Differentiation; Cell Movement; Cell Prolife | 2019 |
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
Topics: Aldosterone; Animals; Arterial Pressure; Body Weight; Cardiac Output; Cell Proliferation; Fibrosis; | 2013 |
Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacing.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Atrial Fibrillation; Atrial Natriuretic Factor; Atr | 2013 |
Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Diet, Sodium-Restricted; Echocardiography; Endoth | 2014 |
Evaluation of docosahexaenoic acid in a dog model of hypertension induced left ventricular hypertrophy.
Topics: Aldosterone; Animals; Arachidonic Acid; Blood Pressure; Disease Models, Animal; Docosahexaenoic Acid | 2013 |
Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzo | 2014 |
Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes.
Topics: Aldosterone; Animals; Cell Line; Fibrosis; Heart Atria; MAP Kinase Signaling System; Mice; Myocytes, | 2013 |
Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors.
Topics: Aldosterone; Animals; Antibodies; Carotid Arteries; Carotid Artery Injuries; Cell Proliferation; Dis | 2014 |
Autocrine and paracrine function of Angiotensin 1-7 in tissue repair during hypertension.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Aut | 2014 |
Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure.
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Cells, Cultured; Conne | 2014 |
Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats.
Topics: Aldosterone; Animals; Blood Pressure; Caspase 1; DNA Nucleotidylexotransferase; Epithelial Sodium Ch | 2014 |
Small dedifferentiated cardiomyocytes bordering on microdomains of fibrosis: evidence for reverse remodeling with assisted recovery.
Topics: Aldosterone; Animals; Antioxidants; Cell Dedifferentiation; Cell Differentiation; Fibrosis; Hyperten | 2014 |
Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide.
Topics: Aldosterone; Animals; Cardiotonic Agents; Chronic Disease; Collagen; Cytochrome P-450 CYP11B2; Disea | 2014 |
Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model.
Topics: Aldosterone; Angiotensin II; Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Catheter Abl | 2014 |
Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans.
Topics: Adrenalectomy; Aldosterone; Animals; Cell Line; Dose-Response Relationship, Drug; Fibroblasts; Fibro | 2014 |
Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Topics: Adrenalectomy; Aldosterone; Animals; Chronic Disease; Cyclosporine; Cytochrome P-450 CYP11B2; Diseas | 2015 |
Rapamycin attenuates aldosterone-induced tubulointerstitial inflammation and fibrosis.
Topics: Aldosterone; Animals; Antibiotics, Antineoplastic; Cell Line; Epithelial-Mesenchymal Transition; Ext | 2015 |
Renal denervation suppresses atrial fibrillation in a model of renal impairment.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Fibrillation; Autonomic Denervation; C-Reactive Protein | 2015 |
Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.
Topics: Acute-Phase Proteins; Aldosterone; Animals; Aorta; Cardiomyopathy, Hypertrophic; Cells, Cultured; Cy | 2015 |
Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice.
Topics: Aldosterone; Animals; Atrial Fibrillation; Atrial Remodeling; Cardiotonic Agents; Cells, Cultured; C | 2015 |
Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis in mice.
Topics: Aldosterone; Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Caspase 1; Enz | 2015 |
Aldosterone effects on glomerular structure and function.
Topics: Aldosterone; Animals; Fibrosis; Glomerular Filtration Rate; Kidney Glomerulus; Male; Oxidation-Reduc | 2015 |
Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis.
Topics: Adipocytes; Adrenal Cortex; Aldosterone; Animals; Cell Line, Tumor; Cells, Cultured; Endothelium, Va | 2015 |
Inducible Knock-Down of the Mineralocorticoid Receptor in Mice Disturbs Regulation of the Renin-Angiotensin-Aldosterone System and Attenuates Heart Failure Induced by Pressure Overload.
Topics: Aldosterone; Animals; Collagen; Disease Models, Animal; Echocardiography; Electrolytes; Fibrosis; Ge | 2015 |
Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue.
Topics: Adipocytes, Brown; Adipocytes, White; Adipose Tissue, Brown; Adipose Tissue, White; Aldosterone; Ani | 2016 |
Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.
Topics: Aldosterone; Animals; Fibrosis; Inflammation; Kidney; Kidney Diseases; Macrophages; Male; Mineraloco | 2016 |
Mesenchymal Stromal Cells Prevent Renal Fibrosis in a Rat Model of Unilateral Ureteral Obstruction by Suppressing the Renin-Angiotensin System via HuR.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Apoptosis; Cell Differentiation | 2016 |
Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol | 2016 |
TRAF3IP2 mediates aldosterone/salt-induced cardiac hypertrophy and fibrosis.
Topics: Adaptor Proteins, Signal Transducing; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cell Adhes | 2016 |
Tissue Inhibitor of Metalloproteinases-1 Regulation by Aldosterone: Breaking the Balance in Cardiac Fibrosis.
Topics: Aldosterone; Fibrosis; Humans; Myocardium; Tissue Inhibitor of Metalloproteinases | 2016 |
Aldosterone Induces Tissue Inhibitor of Metalloproteinases-1 Expression and Further Contributes to Collagen Accumulation: From Clinical to Bench Studies.
Topics: Aldosterone; Analysis of Variance; Animals; Biopsy, Needle; Blotting, Western; Collagen; Disease Mod | 2016 |
The relation among aldosterone, galectin-3, and myocardial fibrosis: a prospective clinical pilot follow-up study.
Topics: Adrenalectomy; Aldosterone; Blood Proteins; Electrocardiography; Female; Fibrosis; Follow-Up Studies | 2016 |
Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibroblast Gr | 2017 |
Renal denervation significantly attenuates cardiorenal fibrosis in rats with sustained pressure overload.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiomyo | 2016 |
Epidermal growth factor receptor signaling mediates aldosterone-induced profibrotic responses in kidney.
Topics: Aldosterone; Animals; Cell Line; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydroc | 2016 |
Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice.
Topics: Aldosterone; Animals; Blood Pressure; Fibrosis; Humans; Interleukin-18; Kidney; Kidney Diseases; Mal | 2016 |
Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo.
Topics: Adaptor Proteins, Signal Transducing; Aldosterone; AMP-Activated Protein Kinases; Animals; Cardiomeg | 2016 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel | 2017 |
The aggravating mechanisms of aldosterone on kidney fibrosis.
Topics: Aldosterone; Fibrosis; Humans; Kidney; Nephrosclerosis; Renin-Angiotensin System | 2008 |
Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction.
Topics: Aldosterone; Animals; Cardiac Catheterization; Corticosterone; Cytochrome P-450 CYP11B2; Disease Mod | 2009 |
Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Collagen Type I; Fibrosis; Gene Expression Regula | 2008 |
Comparison of the effects of intrapericardial and intravenous aldosterone infusions on left ventricular fibrosis in rats.
Topics: Aldosterone; Animals; Disease Models, Animal; Fibrosis; Heart Ventricles; Infusions, Intravenous; In | 2008 |
[Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats].
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Losartan; M | 2008 |
Dexamethasone enhances basal and TNF-alpha-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11beta-hydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Cells, Cultured; Dexamethasone; Fibrosis; | 2009 |
Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules.
Topics: Actins; Aldosterone; Butadienes; Cadherins; Cell Transdifferentiation; Cells, Cultured; Collagen; En | 2008 |
Renal functional, not morphological, abnormalities account for salt sensitivity in Dahl rats.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cyclic GMP; Diastole; Dose-Response Relationsh | 2009 |
Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Vess | 2009 |
Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosteron | 2009 |
Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Chemokine CCL2; Female; Fibrosis; Gene Expression | 2009 |
Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cytokines; Diastole; Drug Therapy, | 2009 |
Are macrophages the foot soldiers in the war waged by aldosterone against the heart?
Topics: Aldosterone; Animals; Blood Pressure; Desoxycorticosterone; Fibrosis; Macrophages; Mice; Mice, Knock | 2009 |
Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.
Topics: Administration, Oral; Aldosterone; Animals; Cardiomegaly; Collagen Type I; Cytochrome P-450 CYP1A1; | 2009 |
The role of Na+-H+ exchanger isoform 1 in aldosterone-induced glomerulosclerosis in vivo.
Topics: Aldosterone; Animals; Cation Transport Proteins; Fibrosis; Glomerulonephritis; Male; Nephrectomy; Ra | 2009 |
Difluoromethylornithine inhibits hypertrophic, pro-fibrotic and pro-apoptotic actions of aldosterone in cardiac cells.
Topics: Aldosterone; Animals; Apoptosis; Biogenic Polyamines; Cells, Cultured; Eflornithine; Fibrosis; Gene | 2010 |
Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Blood Pressure; Eplerenone; Fib | 2010 |
Direct fibrogenic effects of aldosterone on normotensive kidney: an effect modified by 11β-HSD activity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Adrenalectomy; Aldosterone; Animals; Cells, Cultured; C | 2010 |
Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity.
Topics: Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Cell Line; Fibroblas | 2010 |
Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats.
Topics: Aldosterone; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Felodipine; | 2010 |
Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Car | 2010 |
Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients.
Topics: Adult; Aldosterone; Biomarkers; Blood Pressure; C-Reactive Protein; Cardiomyopathies; Case-Control S | 2010 |
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Fibrosis; Heart; Hypert | 2010 |
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2010 |
Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression.
Topics: Aldosterone; Animals; Blood Pressure; Fibrosis; Heart; Immediate-Early Proteins; Interleukin-1; Male | 2011 |
The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hyperte
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Drug Discovery; Drug Evaluation, Preclinical; Fibrosis; Heart | 2011 |
Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.
Topics: Aldosterone; Angiotensin II; Animals; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Diastol | 2010 |
Aldosterone/NaCl-induced renal and cardiac fibrosis is modulated by TGF-β responsiveness of T cells.
Topics: Aldosterone; Animals; Blood Pressure; Collagen; Extracellular Matrix; Fibronectins; Fibrosis; Kidney | 2011 |
[The effect of Aldosterone on the proliferation and collagen production of cardiac fibroblasts].
Topics: Aldosterone; Cell Proliferation; Collagen; Fetal Heart; Fibroblasts; Fibrosis; Humans; Myocardium; R | 2011 |
New take on the role of angiotensin II in cardiac hypertrophy and fibrosis.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Inflammation; Mi | 2011 |
Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Fibrinolysin; Fibrosis | 2011 |
Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Inflammation; Kidney; Male; | 2011 |
Aldosterone promotes atrial fibrillation.
Topics: Aldosterone; Animals; Atrial Fibrillation; Connexin 43; Electrocardiography; Electrophysiologic Tech | 2012 |
A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen; Cytokines; Disease Models, Animal | 2011 |
Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Antihypertensive Agents; Biomar | 2011 |
In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Collagen; D | 2012 |
Endogenous aldosterone is involved in vascular calcification in rat.
Topics: Aldosterone; Alkaline Phosphatase; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals | 2012 |
Myocardial migration by fibroblast progenitor cells is blood pressure dependent in a model of angII myocardial fibrosis.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cell Movement; Collagen; Fibroblasts; Fibrosis | 2012 |
Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Fibrosis; Heart; Immediate-Early Proteins; Infla | 2012 |
[Screening for genes associated with cardiac fibrosis induced by aldosterone].
Topics: Aldosterone; Blotting, Western; Cells, Cultured; Chemokine CCL7; Fetus; Fibroblasts; Fibrosis; Gene | 2012 |
Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
Topics: Aldosterone; Animals; Animals, Newborn; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blo | 2012 |
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D | 2012 |
Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis.
Topics: Aldosterone; Angiotensin Amide; Animals; Fibrosis; Heart; Hypertension; Macrophages; Male; Mice; Mic | 2012 |
[Hypertension-induced fibrosis: a balance story].
Topics: Aldosterone; Angiotensin II; Animals; Bone Morphogenetic Proteins; Cardiomegaly; Disease Models, Ani | 2012 |
Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure.
Topics: Aldosterone; Animals; Autophagy; Disease Models, Animal; Disease Progression; Fibrosis; Heart Failur | 2012 |
Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury.
Topics: Aldosterone; Animals; Disease Models, Animal; Extracellular Fluid; Fibrosis; Glomerulosclerosis, Foc | 2012 |
Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.
Topics: Aldosterone; Amides; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cy | 2013 |
Galectin-3 mediates aldosterone-induced vascular fibrosis.
Topics: Aldosterone; Animals; Blood Pressure; Cells, Cultured; Collagen Type I; Disease Models, Animal; Fibr | 2013 |
CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart.
Topics: Aldosterone; Amino Acid Sequence; Animals; Cell Line; Cyclic GMP; Elapid Venoms; Fibrosis; Heart; He | 2012 |
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cell Size; Dr | 2013 |
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
Topics: Aldosterone; Blood Pressure; Cohort Studies; Collagen; Collagen Type I; Echocardiography; Electrocar | 2002 |
Aldosterone-induced inflammation in the rat heart : role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cardiomyopathies; Cell Division; Cell Movement; Fibrosis; Heart; | 2002 |
Potential importance of glomerular citrate synthase activity in remnant nephropathy.
Topics: Adrenalectomy; Aldosterone; Animals; Citrate (si)-Synthase; Fibrosis; Gene Expression; Kidney Diseas | 2003 |
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.
Topics: Aldosterone; Animals; Blood Pressure; Cytokines; Eplerenone; Fibrosis; Hypertension, Renal; Immunohi | 2003 |
Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
Topics: Administration, Oral; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriur | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis | 2003 |
Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis.
Topics: Adult; Aldosterone; Blood Pressure; Case-Control Studies; Diastole; Echocardiography; Female; Fibros | 2003 |
Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice.
Topics: Aldosterone; Animals; Antigens, Neoplasm; Blood Pressure; DNA-Binding Proteins; Fibrosis; Integrins; | 2003 |
NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats.
Topics: Acetophenones; Aldosterone; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Collagen; Fibro | 2004 |
Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Disease Models, Animal; Drug Th | 2004 |
Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion.
Topics: Aldosterone; Animals; Apoptosis; Blood Pressure; Dilatation, Pathologic; Disease Models, Animal; Ech | 2004 |
From inflammation to fibrosis: a stiff stretch of highway.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Apoptosis; Cell Adhesion Molecules; Collagen | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Acetylcholine; Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Collagen | 2004 |
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cell Size; Eplerenone | 2004 |
Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system.
Topics: Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Biomarkers; Blood Pressure; Cyclic N-Ox | 2004 |
Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; A | 2004 |
Cellular basis for therapeutic choices in heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; A | 2004 |
Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-beta1 in the heart.
Topics: Aldosterone; Angiotensin II; Animals; Chemokine CCL2; Deferoxamine; Enzyme Inhibitors; Ferritins; Fi | 2005 |
Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats.
Topics: Actins; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazol | 2005 |
Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist.
Topics: Adrenergic beta-Agonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anim | 2005 |
Oxidative stress and profibrotic action of aldosterone.
Topics: Aldosterone; Animals; Fibrosis; Hypertension, Renal; Oxidative Stress; Renin-Angiotensin System | 2005 |
Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Bradykinin B2 Receptor A | 2004 |
Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Angiotensin II; Angiotensinogen; Animals; Animals, Genet | 2005 |
Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen.
Topics: Aldosterone; Angiotensinogen; Animals; Animals, Genetically Modified; Brain; Cell Size; Fibronectins | 2005 |
Animal models of cardiac fibrosis.
Topics: Aldosterone; Angiotensin II; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Diseases; | 2005 |
Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Glu | 2005 |
Prostacyclin protects against elevated blood pressure and cardiac fibrosis.
Topics: Aging; Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Cardiotonic Agents; Cyclooxyge | 2005 |
Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Collagen; Ectodysplasins; Fibrosis; Heart; Hypertension | 2005 |
Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone.
Topics: Aldosterone; Animals; Apoptosis; Cardiomegaly; Fibrosis; Heart; Hypoparathyroidism; Male; Myocardium | 2006 |
The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
Topics: Actins; Aldosterone; Animals; Blotting, Western; Cytochrome P-450 CYP11B2; Drug Therapy, Combination | 2006 |
Induction of kidney injury molecule-1 in homozygous Ren2 rats is attenuated by blockade of the renin-angiotensin system or p38 MAP kinase.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atrial | 2007 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Prolife | 2006 |
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis; | 2006 |
Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
Topics: Aldosterone; Animals; Cells, Cultured; Chronic Disease; Extracellular Signal-Regulated MAP Kinases; | 2007 |
Aldosterone antagonism fails to attenuate age-associated left ventricular fibrosis.
Topics: Aging; Aldosterone; Animals; Atrial Natriuretic Factor; Collagen; Collagen Type III; Female; Fibrosi | 2007 |
Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation.
Topics: Aldosterone; Analysis of Variance; Angiotensin II; Animals; Blood Pressure; Body Weight; Cytokines; | 2007 |
Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Extracellular Matrix; Fenofibrate; Fibrosis; Heart; Heart Rate | 2007 |
Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone.
Topics: Aldosterone; Animals; Coronary Vessels; Disease Models, Animal; Feces; Fibrosis; Homeostasis; Hypera | 2007 |
Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone.
Topics: Aldosterone; Animals; Canrenoic Acid; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type | 2008 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinog | 2007 |
Aldosterone-and-salt-induced cardiac fibrosis is independent from angiotensin II type 1a receptor signaling in mice.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Ca | 2007 |
Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium.
Topics: Aldosterone; Animals; Antibodies; Antibody Specificity; Cells, Cultured; Connective Tissue Growth Fa | 2008 |
Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Down-Regulation; Fibrosis; Gene Expression; Hyper | 2008 |
Aldosterone: from biosynthesis to non-genomic action onto the proteome.
Topics: Adrenal Glands; Aldosterone; Animals; Calcium; Corticosterone; Cytochrome P-450 CYP11B2; Desoxycorti | 2008 |
Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells.
Topics: Aldosterone; Animals; Cells, Cultured; Drug Synergism; Extracellular Matrix; Fibroblasts; Fibrosis; | 2008 |
Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Fibrosis; Immunohistochemistry; Kidney; Kidney | 2008 |
Determinants of cardiac fibrosis in experimental hypermineralocorticoid states.
Topics: Adrenalectomy; Aldosterone; Animals; Desoxycorticosterone; Drug Combinations; Fibrosis; Fludrocortis | 1995 |
Biological determinants of aldosterone-induced cardiac fibrosis in rats.
Topics: Aldosterone; Animals; Blotting, Northern; Collagen; Fibrosis; Heart; Histocytochemistry; Hypertensio | 1995 |
Bradykinin receptor and tissue ACE binding in myocardial fibrosis: response to chronic angiotensin II or aldosterone administration in rats.
Topics: Aldosterone; Animals; Autoradiography; Fibrosis; Injections, Subcutaneous; Male; Myocardium; Peptidy | 1995 |
Aldosterone and cardiac fibrosis: in vitro studies.
Topics: Aldosterone; Androstanols; Angiotensin II; Animals; Cells, Cultured; Collagen; Fibroblasts; Fibrosis | 1994 |
[Restructuring of the collagen network in hypertension: role of the angiotensin-aldosterone system].
Topics: Aldosterone; Animals; Collagen; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Renin | 1993 |
Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone.
Topics: Aldosterone; Angiotensin II; Animals; Autoradiography; Blood Pressure; Collagen; Coronary Vessels; F | 1993 |
Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride.
Topics: Aldosterone; Amiloride; Animals; Cardiomyopathies; Cicatrix; Collagen; Disease Models, Animal; Drug | 1993 |
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Hyperaldosteronism; Hypertension; | 1993 |
Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone.
Topics: Actins; Aldosterone; Angiotensin II; Animals; Cell Division; Fibroblasts; Fibrosis; Heart; Infusions | 1995 |
The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis.
Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Body Weight; Canr | 1996 |
Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Autoradiography; Binding Sites; Endomyocardial Fibrosis | 1997 |
Fibrosis and myocardial ACE: possible substrate and independence from circulating angiotensin II.
Topics: Aldosterone; Angiotensin II; Animals; Autoradiography; Endomyocardial Fibrosis; Female; Fibrosis; Ma | 1994 |
Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade.
Topics: Aldosterone; Angiotensin II; Animals; Benzimidazoles; Calcium; Calcium Channel Blockers; Collagen; D | 1998 |
Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo.
Topics: Aldosterone; Angiotensin II; Animals; Arterioles; Blood Pressure; Cell Division; Collagen; Coronary | 1998 |
In vivo left ventricular function and collagen expression in aldosterone/salt-induced hypertension.
Topics: Aldosterone; Animals; Collagen; Electrolytes; Fibrosis; Guinea Pigs; Hormones; Hypertension; Hypertr | 1998 |
Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis.
Topics: Aldosterone; Animals; Autoradiography; Collagen; Fibrosis; Heart; Male; Myocardium; Rats; Rats, Spra | 1999 |
Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; C | 1999 |
Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomeg | 2000 |
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blotting, Northern; Creatinine; Disease Progre | 2000 |
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
Topics: Age Factors; Aldosterone; Animals; Aorta; Carotid Arteries; Endomyocardial Fibrosis; Fibrosis; Hemod | 2001 |
Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cell Division; Colla | 2001 |
Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction.
Topics: Acute Disease; Aged; Aldosterone; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhi | 2001 |
Reduced activity of 11 beta-hydroxysteroid dehydrogenase in patients with cholestasis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; 11-beta-Hydroxysteroid Dehydrogenases; Active Transport | 2001 |
Prevention of radiation-induced nephropathy and fibrosis in a model of bone marrow transplant by an angiotensin II receptor blocker.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bone Marrow Transpl | 2001 |
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Topics: Aldosterone; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Bo | 2002 |
Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1.
Topics: Aldosterone; Animals; Antihypertensive Agents; Aorta; Aortic Diseases; Blood Pressure; Body Weight; | 2002 |
Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Disease Models, Animal; Fibrosis; Hype | 1992 |
Remodeling of the rat right and left ventricles in experimental hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Fibrosis; Heart Ventricles; Hemodynami | 1990 |